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CHAPTER I
INTRODUCTION
Calcium (Ca2+) functions as an important intracellular element that
underlies essential cellular processes including muscle contraction, synaptic
transmission, secretion of hormones, and gene expression (Fill and Copello,
2002; Zhang and Brown, 2004). In the heart, Ca2+ is the signaling massager for
cardiac excitation-contraction coupling (E-C coupling) which is a chain reaction,
and Ca2+ concentration fluctuation can be converted to cardiac contraction and
relaxation. Moreover, the intracellular calcium concentration [Ca2+]i should be
finely adjusted to maintain its homeostasis, which helps maintain various cellular
functions, such as: gene transcription (Atar et al, 1995) and post-translational
protein modification, both of which are very critical for cell viability (Anderson et
al, 2007, George et al, 2007). Alterations to this fine Ca2+ homeostasis could lead
to abnormal gene transcription for hypertrophic remodeling, impaired contractile
function, and arrhythmogenicity.
The cardiac ryanodine receptor (RyR2) is the Ca2+ release channel
located in the sarcoplasmic reticulum (SR) membrane, and is the central link in
cardiac EC coupling to control release of SR stored Ca2+, accounting for up to
90% of total Ca2+ in EC coupling cycle (Bers, 2001). Over the past ten years,
diastolic Ca2+ leak through dysfunctional RyR2 has been recognized as an
1
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important factor contributing to altered Ca2+ homeostasis in heart failure (HF).
Evidence in several reports shows that abnormality within the RyR2 causes
increased diastolic Ca2+ leak, leading to contractile and relaxation dysfunction
(Yano et al 2000; Ai X, et al, 2005; Wehrens et al, 2006). Moreover, the abnormal
Ca2+ leak through RyR2 could lead to lethal arrhythmia (Wehrens et al 2003).
Now it is well known that RyR2-mediated SR Ca2+ leak could activate inward
current through Na/Ca exchanger (NCX) (Vermeulen et al, 1994), and further
evoke delayed after depolarizations (DADs), which has been proven to be the
leading reason for ventricular tachyarrhymia and sudden cardiac death (Pogwizd
and Bers 2004). In HF there is an enhanced diastolic SR Ca2+ leak and other
changes in electrophysiological substrate (like up-regulation of NCX) that greatly
enhance the propensity for triggered cardiac arrhythmias (Pogwizd and Bers,
2002). Approximately 50% of heart failure (HF) patients die of DAD related
sudden cardiac death (Noseworth et al 2008). All those properties now make
RyR2 being a potential therapeutic target for anti-HF and anti-arrhythmia.
A leading hypothesis for explaining the RyR2 dysfunction, enhanced SR
Ca2+ leakiness in HF and lethal arrhythmias, is defective interaction between the
N-terminal (N: 0-600) and the central (C: 2000-2500) domains (Yamamoto and
Ikemoto, 2002). According to this concept, in the resting state, the tight
interaction between N-terminal and central domains acts as a regulatory switch
for channel gating activity. This tight interdomain interaction, termed “domain
zipping” can stabilize the channel in the fully closed state (Yamamoto and
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Ikemoto, 2002). Weakening of these interdomain interactions may be caused by
mutations in either the N-terminal or central regions of RyR2 (Uchinoumi et al,
2010), resulting in an increased opening probability of the RyR2 and leakiness of
Ca2+. A synthetic peptide (DPc10) corresponding to the central domain (DP24602495) of RyR2, was reported to specifically associate with the N-terminal domain
competing with its zipping to the central domain, and that the N-domain/DPc10
association can unzip and destabilize RyR2 (via domain unzipping), to increase
Ca2+ leakiness (Oda T, et al, 2005).
Calmodulin (CaM) is a ubiquitous and highly conserved Ca2+ binding
protein which regulates multiple cellular processes. With 148 highly conserved
residues and ~16.7kDa molecular weight, CaM has two globular Ca2+ binding
domains with E-F hands, connected by a flexible tether helix (Jurado et al, 1999).
At high [Ca2+], Ca2+ can bind cooperatively to CaM and result in a conformational
change that translate intracellur Ca2+ signal to diverse targets. Working as a
critical regulator for SR Ca2+ release channel, CaM binds to RyR2
stoichiometrically (four CaMs per tetrameric RyR2). Cryo-EM based 3D RyR
reconstruction showed that Ca-free CaM (apoCaM) binds to a cleft in the
cytosolic domain 3 (AA 3614-3643) (Moore et al, 1999; Wagenknecht et al 1994),
with a distance of 60-70Å to FKBP12.6 on the same side (Cornea et al, 2009;
Guo T et al 2011). FKBP12.6 was also reported to bind RyR2 tightly as an
important regulator, but some aspects are still highly controversial (Brillantes AB,
et al 1994; Marx SO et al 1998; Barg S et al, 1997; Guo T, et al 2010). Mutations
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(RyRADA) to the highly conserved CaM binding region can severely inhibit CaM
binding to RyR2 and cause severe hypertrophic cardiomyopathy and early death
in animal models (Yamaguchi et al, 2007). In a non-ischemic rabbit HF model,
CaM association to RyR2 was decreased with unchanged total CaM (Ai X, et al,
2005). A recent study indicates that defective CaM binding to RyR2 is involved in
catecholaminergic polymorphic ventricular tachycardia (CPVT) associated RyR2
dysfunction and lethal arrhythmia (Xu X, et al, 2010). All these reports suggest
that CaM-RyR2 interaction could be a critical molecular substrate for arrhythmias
and HF pathogenic processes.
Here through FRET (fluorescent resonance energy transfer) detection, we
for the first time identified RyR2-bound CaM from its numerous binding target
proteins, and characterized CaM-RyR2 interaction properties in both normal and
HF cardiomyocytes. The knock-in mice (RyRADA), with genetically disrupted CaMRyR2 association while the interaction with other CaM targets are not affected,
were used to estimate the percentage of Z-line bound CaM that is due to RyR2.
Furthermore the patho-physiological consequences of CaM for RyR2 regulation
were defined through function test.
DPc10 has been worked as useful molecular reagents to study RyR2’s
function and structure. In this study, through fluorescent tagging we can
characterize the binding kinetics of DPc10 to the RyR2 macromolecular complex
in the relatively intact environment provided by saponin-permeabilized ventricular
myocytes. Furthermore, we defined CaM as a critical stabilizer for RyR2 through
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this RyR2 unzipping peptide and revealed the relationship between CaM and
RyR2 domains interaction (domain zipping).
This accomplishment enriched our understanding about RyR2-CaM
interaction and functional effects on RyR-mediated Ca2+ release in cardiac
myocytes. This will also expand our knowledge of molecular mechanisms that
underlie arrhythmogenesis and HF. Importantly, it could pinpoint a potential
molecular target responsible for Ca2+ triggered arrhythmias and may translate
into the development of novel therapeutic strategies.

CHAPER II
REVIEW OF RELATED LITERATURE
Cardiac Excitation – Contraction Coupling
Cardiac Excitation-contraction coupling (ECC) is an essential physiological
process in which an electrical stimulus is converted to cardiac contraction,
resulting in blood being pomped out to meet the need of the whole body. An
action potential (AP), normally induced by pacemaker cells in Sinoatrial (SA)
node, can propagate and reach the ventricular myocytes through cardiac
conduction system (atrial muscle, atrio-ventricular node, His bundle, bundle
branches and Purkinje fibers). Delivered AP can activate voltage-dependent Na
channel and produce a very fast upstroke Na current, which brings resting
membrane potential (Em) from -80 mV up to ~+30-50 mV. Then voltagedependent L-type calcium (Ca2+) channels (LTCC) are activated and causing the
Ca2+ influx, which triggers a subsequent release of Ca2+ stored in the
sarcoplasmic reticulum (SR). This SR Ca2+ release through the calcium-release
channels (ryanodine receptors / RyRs), works as a positive feedback response
and is termed Ca2+-induce Ca2+ release (CICR, Fabiato 1985). As total [Ca2+]i,
released from SR and entered through LTCC, rises to > 100 uM, the free Ca2+
binds to troponin-C (TN-C) that is part of the regulatory complex attached to the
thin filaments. Once bound with Ca2+, TN-C undergoes a conformational change
6
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and exposure of a binding site on the actins for myosin head. The physical
contact of actin and myosin head results in ATP hydrolysis that supplies energy
for a slide between the myosin and actin. This sliding shortens the length of
cardiomycyte and commits the cardiac contraction. Relaxation occurrs after the
sequestering of cytosolic Ca2+ via SR Ca2+-ATPase (SERCA), sarcolemmal
sodium-calcium

exchanger

(NCX),

sarcolemmal

calcium

ATPase

and

mitochondrial Ca2+ uniporter. In mouse ventricular myocytes, ~90% Ca2+ needed
for contraction is taken up by SERCA back into SR; ~10% Ca2+ is excluded from
the cell by NCX; < 1% Ca2+ is excluded through sarcolemmal calcium ATPase or
taken by mitochondrial uniporter (Bers 2001). The lowering of intracellular Ca2+
makes troponin C return to cover the active binding site and to separate myosin
head from actin, which results in the end of contraction and causing relaxation.
Cellular Structure Basis of Cardiac EC-Coupling
1. Myofibrils and sarcomere.
Muscles are composed of tubular muscle cells (myocytes), and muscle
cells are mainly (45~60%, Bers, 2001) composed of tubular myofibrils (Fig. 1),
which is mainly constituted by myosin (thick filament) and actin (thin filament).
Striated myofibrils, like skeletal and cardiac muscle, are composed of 1.8 um size
repeating sections of sarcomere that is the fundamental contractile unit (Fig. 1).
Z-line, where actin molecules (thin filaments) are attached (Fig 1), forms the
border of the sarcomere (Bers, 2001).
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2. Sarcolemma and transverse tubules.
The sarcolemma is the cell membrane of a muscle cell. In striated
muscles, the cell membrane invaginates regularly into the cytoplasm of the cell,
forming a special membranous tubule structure termed transverse tubules (Ttubules) (Fig. 1). These T-tublues allow a simultaneous penetration of
sarcolemma depolarization into the interior of the cell for a synchronous Ca2+
release and contraction. In cardiac muscle, T-tubule is typically located at Z-line
and forms junctional coupling with terminal cisternaes (enlarged bulbous ends of
the SR at Z-line region), constituting an arrangement called a diad (Fig 1). Ttubules are the major sites for EC coupling; many essential components, like
LTCC, RyR, and NCX, are concentrated at the T-tuble region. In the experiments
named “detubulation”, low osmolarity can disrupt T-tubule. Through detubulation,
myocyte’s capacitance proportional to the cell surface decreased by ~30%
(Kawai M, et al, 1999), while ~87% of ICa and almost all NCX current are lost due
to detubulation (Kawai M, et al, 1999; Yang Z, et al, 2002). With ß-adrenergic
stimulation, the increase of LTCC current is greater for normal cells than
detubulated cell, indicating a better coupling of LTCC in T-tubule to the second
messager than that on the surface of sacolemma (Brette F, et al, 2002; Brette F
& Orchard C, 2003).

9

Myofibril
Z-line

M-line

Z-line

Fig 1: Schematic diagram of the mammalian cardiac muscle.
Sarcomere refers to the myofibril between Z-lines. T-tubules are co-locolized
with Z-lines. Mitochondrias are filled into the zones between Z-lines.
(Fawcett & McNutt, 1969)
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3. Sarcoplasmic reticulum (SR).
The SR is an intracellular organelle and the main Ca2+ storage for cardiac
myocytes. The structure is analogous to the endoplasmic reticulum present in
other types of cells, with a more regular network structure, specialized for the
efficient Ca2+ release required for CICR. The SR has a homogenous membrane
geometry, which can be divided into junctional SR (JSR) and longitudinal SR
(LSR) (Fig 1). The LSR is distributed throughout the myoplasm and is thought to
be mostly concerned with Ca2+ uptake. The JSR, which is also called the terminal
cisternae (Fig 1), exists in close proximity to T-tubules. In junctions between JSR
and T-tubule, a bridging “foot” structure was found (Franzini-Armstrong, 1970).
This junctional foot structure turned out to be highly specialized RyRs and
function as Ca2+ release channels. In the SR lumen, there are three known Ca2+
binding proteins: (1) Calsequestrin is thought to bind the majority of Ca2+ in the
SR and is highly localized to the JSR; (2) histidine-rich Ca2+-binding protein
(HRC) and (3) sarcalumenin, are distributed throughout the SR suggesting the
role in LSR Ca2+ buffering (Bers 2004).
Since the SR is a single, physically continuous, and tubular intercellular
compartment, it was first considered as a homogeneous Ca2+ storage. However,
with some functional heterogeneity found, this simplistic view is not correct
(Papps et al, 2003). Now the widely accepted notion is that: physically the SR is
continuous tubular network and lumenally connected, but it is spatially and
functionally heterogeneous. This heterogeneity is established by the nonuniform
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distribution of SR Ca2+-handling proteins: (1) the main SR luminal Ca2+-buffuer
proteins, calsequestrin, are mainly in JSR; (2) the Ca2+ uptake pump, SERCA, is
mainly in LSR; and (3) the SR Ca2+ release channels, ryanodine receptors
(RyRs), is mainly in JSR (Papp s, et al, 2003). The nonuniform distribution of
these Ca2+-handling proteins provides the functional division of SR, rather than
the stuctural divisions (JSR and LSR).

12

Fig 2: Schematic diagram of monomer RyR2 sequence.
Associated important regulatory proteins and phosphorylation sites are
indicated on cytosolic side. 6 transmembrane domains form the channel
core with putative core region GIG. Triadin and Junctin are coupled with
channel core and linked with calsequestrin (CSQ) (Bers, 2001).
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SR Ca2+ release Channel (RyR)
RyRs, as intracellular Ca2+ release channels, play a central role in
excitation-contraction coupling (ECC). This channel controls the release of SR
stored Ca2+ accounting up to 90% total Ca2+ in EC coupling cycle (Bers 2001). As
a family of Ca2+ release channels found on intracellular Ca2+ store/release
organelles like SR, RyRs are expressed in many types of cells and three
isoforms have been identified: RyR1 is primarily in skeletal muscle; RyR2 is the
main isoform in cardiac muscle; RyR3 is expressed in various tissues at low
level. In striated muscles, RyR1/RyR2 is concentrated at the Z-line or T-tubule
region in the packed arrays. In a cardiac junction ( at Z-line or T-tubule), it is
estimated up to 200 RyRs are packed into 60 – 100 nM diameter circle region for
a typical cardiac couplon, in which RyR tetramers are connected through cornercontact and implied an functional coupling for RyRs gating in the couplon (Marx
et al 2001; Bers, 2001).
1. RyR structure:
As the biggest ion channel discovered so far, RyR is composed of four
monomers that form a homotetramer and comprise a single RyR channel (Bers
2001). Each monomer has over 5000 amino acids and ~560 kDa molecular
weight. The majority of the amino acid sequence folds to form the cytoplasmic
domain, which provides docking sites for most channel regulators like CaM,
FKBP, Ca2+, kinases and phosphatases. Only a small part of the c-terminal
sequence forms the transmembrane domain and channel pore (Fig.2), where the
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loop between 5th and 6th transmembrane domain (Zhao M, et al, 1999) works as
a putative pore loop (Fig 2, Bers 2004). 4 pore loops form the narrowest part of
the channel pore that works as ion selection and mediates Ca2+ passage (Bers
2004). Triadin and junctin are SR membrane proteins which interact with RyR
transmembrane domain (Fig 2). Calsequestrin, the major intra-SR Ca2+-binding
protein, linked to triadin and junction in RyR (Fig 2). And three proteins form a
complex that is thought for the sensation of SR lumenial Ca2+ level and the
gating of RyR (Caswell AH, et al, 1991; Knudson CM, et al, 1993; Jones LR, et
al, 1993; Zhang L, et al, 1997).
2. Regulation of RyR
a. Ca2+, Mg2+, and ATP
Ca2+ is the charge carrier conducted by RyR in EC coupling; it also works
for RyR modulation from cytoplamic and SR lumen sides. In single channel
experiments, cytoplamic Ca2+ shows two-phase regulation for RyR1. Low Ca2+
concentration (1-10 μM) activates RyR1 by binding to specific high-affinity sites;
high Ca2+ concentration (1-10 mM) inhibits RyR1 by binding to less selective lowaffinity Ca2+ sites (Copello et al., 1997; Meissner 1994; Meissner et al. 1997).
Cytoplamic Ca2+ is also involved in RyR regulation through CaM and CaMKII
(reviewed in CaMKII section). For the RyR regulation by Ca2+ from the lumen
side, it was shown that the increased luminal Ca2+ level can enhance the
sensitivity of RyR in single channel recording (Györke and Györke 1998; Laver et
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al. 2004). The complex of calsequestrin, triadin, and junctin is reported as SR
luminal Ca2+ sensor to regulate RyR from luminal side (Györke et al. 2004).
Mg2+ in the physiological concentration works as an inhibitor of RyR,
probably by binding to the Ca2+ site. Mg2+ is believed to bind to Ca2+ high affinity
site competitively to reduce opening of RyR; while for low-affinity Ca2+ site, Mg2+
binding presents a direct inhibition (Meissner et al, 1986; Laver et al; 1997).
ATP can activate both RyR1 and RyR2, but differently. Invitro studies
showed that ATP can activate RyR1 in the absence of Ca2+, but Ca2+ is needed
for maximal activation (Meissner et al, 1984 and 1986; Laver et al, 2001). In the
RyR2 case, the channel can’t be activated by ATP without Ca2+, and ATP can
sensitize RyR2 to Ca2+ but the effect is smaller than that for RyR1. Considering
that under physiological conditions most ATP is in a complex with Mg2+, so in cell
experiments the activation of ATP is mixed with the inhibition of Mg2+ (Lanner et
al, 2012), and therefore it is hard to differentiate those effects.
b. FKBP12/12.6
FKBP12 and FKBP12.6 are also termed as calstabin1 and calstabin2
respectively. They physically bind to RyR monomer at the same binding site in
1:1 manner (Timerman et al. 1993 and 1996). In skeletal muscle, FKBP12
associates with RyR1 with a relatively low affinity (~1uM) and stabilize the
channel in the full closed state (Timerman et al., 1996, Brillantes et al., 1994).
Removal of FKBP12 from RyR1 by pharmacologic depletion or genetic knock-
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out, can increase channel open probability and prolong channel mean open time
(Shou et al. 1998; Marx et al. 1998; Ahern et al. 1997).
In cardiac myocytes, FKBP12.6 preferentially binds to RyR2 with very high
affinity (Timerman et al. 1993; Guo et al. 2010). Some studies showed that
FKBP12.6 plays an important role for RyR2 gating to stabilize the channel in a
fully closed state (Kaftan et al., 1996; Xiao et al., 1997, Xin et al., 2002). By
contrast, other group’s study challenged this opinion (Timerman et al. 1996, Xiao
et al. 2007a). The detail for FKBP12.6’s function on RyR2 will be reviewed in
FKBP section.
c. Calmodulin (CaM)
CaM binds to RyR monomer in a 1:1 rate (Fruen et al. 2000). As an
important RyR regulator, CaM regulates RyR1 and RyR2 activity differently and
Ca2+-dependently. For RyR1, CaM increases the open probability at low
(<100nM) [Ca2+] but inhibits channel activity at high (>1uM) [Ca2+] (Rodney et al,
2000). However, for RyR2, CaM inhibits the channel activity at both low and high
[Ca2+] (Tripathy et al. 1995; Yamaguchi et al. 2005). Moreover, CaM also can
regulate RyR indirectly through CaMKII. Details will be further reviewed in CaM
section.
d. Sorcin
Sorcin is a 22 kDa Ca2+-binding soluble protein and associates with RyR2
when Ca2+ is elevated (Meyers et al., 1995; Meyers et al., 1998). Lipid bilayer
studies showed that sorcin reduced RyR open probability (Po) and this
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depression could be relieved by PKA-dependent phosphorylation (Farrell et al.,
2003). In intact myocytes, dialyzing sorcin into the cell can reduce Ca2+ transient
amplitude with no effect to LTCC current (Farrell et al, 2003).

Furthermore,

transient over expression of sorcin via adenoviral vector showed a decreased
Ca2+ transient with the unchanged SR Ca2+ load (Seidler et al., 2003). All the
studies suggest that sorcin, at high [Ca2+]i, is similar to CaM which inhibits the
Ca2+ release from RyR2 in Ca2+-dependent manner, but this inhibition can be
relieved by low Ca2+ and PKA activation.
e. PKA, CaMKII and phosphatases
Through muscle A kinase anchoring protein (mAKAP), PKA associates
with RyR2 at 3003-3039 (Fig. 2) amino acids (Marx et al, 2001). In the classic
physiological “fight or flight” situation, sympathetic nervous system (SNS) can
cause ß-adrenergic stimulation, which results in larger and faster Ca2+ transient
and consequently stronger and faster muscle contraction. In this process, the
activated PKA mainly phosphorlates 4 targets to cause this physiological
respone: 1. phosphorylation of troponin I decreases myofilament Ca2+ sensitivity
causing the faster relaxation; 2. phosphorylation of LTCC increases ICa; 3.
phosphorylation of phospholamban (PLB) increases SERCA Ca2+ uptake rate
and SR Ca2+ load; 4, phosphorylation of RyR alters its gating (Bers 2001).
Regarding

RyR,

Marx

et

al

found

that

PKA-dependent

RyR

phosphorylation at Ser-2809 can dissociate FKBP12.6 from the RyR and then
enhanced single RyR’s open probability in bilayers experiment (Marx et al, 2000;
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2001). But other groups found that phosphorylation of RyR by cAMP-dependent
PKA activation can not cause FKBP12.6 dissociation (Xiao et al, 2004; Guo et al,
2010). Moreover in PLB knock-out mouse, where SR Ca2+ load can not be
increased by PLB-phosphorylation, the resting Ca2+ spark frequency, which
worked as an index for RyR activity, is unchanged with PKA activation (Li et al,
2002). So another explanation is that the increased Ca2+ spark frequency by
cAMP is largely due to increasing ICa and SR Ca2+ load by PKA activation (Bers
2004). Thus the RyR regulation by PKA phosphorylation is still controversial.
CaMKII is a multifunctional serine/threonine kinase and į isoform is
primarily expressed in heart (Edman et al, 1994). CaMKII can coimmunoprecipitate with RyR2, but the interaction sequence is still not known
(Zhang et al, 2003). CaMKII has a catalytic domain, a central regulatory domain
and an association domain. CaMKII can be activated through Ca2+/CaM binding
to regulatory domain and displacing the auto-inhibitory domain. Guanine
nucleotide exchange protein (Epac) and oxidation are also reported to activate
CaMKII through different pathways (Pereira et al, 2007; Erickson et al, 2008). In
general, CaM is critical for CaMKII activation. Once CaM/Ca2+ is bound, the
kinase retains 100% activity. Autophosphorylation can keep 20-80% maximal
CaMKII activity despite of CaM dissociation (Meyer et al, 1992; Maier et al, 2003)
CaMKII can modify RyR through phosphorylation at up to 6 sites (Zucchi
et al, 1997), including Ser-2809 that also is the target for both PKA and PKG
(Witcher et al, 1991; Wehrens et al, 2004; Rodriguez et al, 2003; Huke and Bers
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2007). Now Ser2814 is thought exclusively for CaMKII phosphorylation (Wehrens
et al, 2004). Most studies on the effect of CaMKII phosphorylation on RyR are
based on single channel and SR vesicle experiment with mixed results, which
showed either increased (Wehrens et al, 2004; Hain et al, 1995) or decreased
channel opening (Lokuta et at, 1995). In intact and permeabilized cells, Bers’ lab
indicates that CaMKII can increase SR Ca2+ release for a given SR Ca load (Li et
al, 1997; Guo et al, 2006). However, the data from Wu et al. (2001) showed
decreased amplitude of Ca2+ transients after CaMKII activation. It could be that
diasolic SR Ca2+ leak dramatically decreases the SR Ca2+ content and
secondarily affects Ca2+ transient. So we think that under physiological
conditions CaMKII phosphorylation exhibits a strong activating effect on RyR
opening. CaMKII also plays an important pathological role, which is going to be
reviewed in a later section.
Phosphates, PP1 and PP2a, are reported to associate with RyR2
indirectly through anchor protein spinophilin and PR130 respectively. The main
function for phosphatases is to dephosphorylate the phosphorylated RyR2, thus
keeping

the

channel

dephosphorylation

in

(Marx

right
et

al,

balance

between

phosphorylation

2001).

PP1

proposed

is

mainly

and
to

dephosphorylate both Ser2809 and Ser2814, while Ser2814 is thought to be
PP2a function site (Huke & Bers, 2008).
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f. Calsequestrin, Junctin and Triadin
Calsequestrin (CSQ), as the major intra-SR Ca2+ buffer, works with junctin
and triadin to form a complex coupled with RyR (Fig 2). As the low-affinity but
high-capacity Ca2+-binding protein, two type of CSQ isoforms are expressed,
CSQ1 is in skeletal muscle and CSQ2 is mainly in cardiac muscle. A current
model hypothesizes that the elevation of luminal Ca2+ weakens the interaction of
CSQ complex causing SR Ca2+ release to maintain SR Ca2+ content (Zhang et
al, 1997). Moderate over expression of CSQ can increase SR Ca2+ load and Ca2+
transient amplitude, thereby prolong SR Ca2+ release time (Terentyev at al,
2003). CSQ2 knockout mouse showed normal SR Ca2+ release and cardiac
contractility, but exposure to catecholamines can cause an increase in SR Ca2+
leak making this mouse susceptible to catecholaminergic ventricular arrhythmias
(Knollmann et al, 2006).
g. Caffeine, Ryanodine and Tetracaine
These three pharmacological compounds are broadly used as exogenous
modulators for RyR function studies. Caffeine can increase the sensitivity of RyR
to Ca2+ (Sitsapesan et al, 1990). Low concentration (2-5mM) worked as
sensitizer for SR Ca2+ release; high concentration (10mM) can completely open
RyR and is used extensively for evaluation of SR Ca2+ content. Ryanodine, a
plant alkaloid, binds RyR with high affinity causing bimodal effects. In single
channel recording, low dosage of ryanodine can increase SR Ca2+ release; high
concentration of ryanodine can block RyR completely (Meissner, 1986). The

21
binding site of ryanodine is proposed to be the channel pore (Callaway et al,
1994); it was reported that the diameter of RyR pore could be changed by
ryanodine binding (Tinker and Williams, 1993; Tu et al, 1994); RyR opening can
promote ryanodine binding and keep the channel in the open state (Chu et al,
1990). Tetracaine is a potent local anesthetic, which can bind to RyR in a
reversible manner. At low concentrations, tetracaine causes an inhibition of SR
Ca2+ release; while at high concentrations, tetracaine blocks SR Ca2+ release
completely (Györke et al, 1997)
Ca2+ Sparks, Ca2+ transients and Ca2+ waves
The Ca2+ spark is a local increase in the concentration of intracellular Ca2+
and regarded as the elementary unit of SR Ca2+ release. It comes from the
opening of a group of SR Ca2+ release channels (RyRs, 6-20) and the release
normally does not propagate to surrounding sites (Blatter et al, 1997;
Lukyanenko et al, 2000). It can be detected with a laser scanning confocal
microscope and fluorescent Ca2+ indicator (Cheng et al, 1993). A prevailing
concept stated that the whole cell global Ca2+ release (Ca2+ transient) triggered
by L-type Ca2+ current is the summation of Ca2+ sparks spatially and temporally
(Wier and Balke, 1999). When a Ca2+ spark is large enough to activate other
Ca2+ release channels around through CICR (calcium induce calcium release), it
can cause a propagation of Ca2+ sparks which is termed as “Ca2+ wave”. A “fire
diffuse fire” mechanism on the basis of CICR is thought to underlie Ca2+ waves:
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Ca2+ released during wave propagation at one site by “firing” diffuses to adjacent
sites (Stern, 1992). Then corresponding rise in Ca2+ concentration induces
another CICR which is the next firing and carries on the wave (Stern, 1992;
Keizer et al., 1998). Ca2+ wave is therefore regarded as spontaneous SR Ca2+
release, which is thought the summation of not temporally synchronized Ca2+
sparks. Some studies showed that Ca2+ wave can greatly increase diastolic Ca2+
and then trigger cardiac arrhythmia.
SR Ca2+ leak
The SR, as the highly special intracellular Ca2+ store organelle, contains ~
1mM free Ca2+ and ~ 2.7 mmol/L total Ca2+ (Shannon and Bers, 1997; Shannon
et at, 2003), while the diastolic cytosol [Ca2+] is 50-100nM. Due to this large
chemical driving force, there is a silent efflux of Ca2+ from SR to cytosol under
resting conditions, which is termed as “SR Ca2+ leak” (Gomez et at, 1996; Zalk et
al, 2007). This Ca2+ leak is primarily mediated by RyR and can be detected in
intact cell through Ca2+ sparks, which indicate a local Ca2+ increase by ~200nM
within 2 um spatial diameter and last about 50 ms (Bers, 2001; Cheng et al,
1993).

These irregular and spontaneous leak events, as a comparison to

synchronized SR Ca2+ release (Ca2+ transient) by stimulation, are only defined to
happen in resting condition. Although Ca2+ spark is well-established intracellular
local SR Ca2+ release event in cardiomyocytes, in adult mammalian skeletal
muscle this phenomenon is rarely observed. The reason could be the property of
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RyR1, which is activated very differently through physical interaction between Ltype Ca2+ channel and RyR1, not through CICR. This section is going to focus on
cardiac myocytes SR Ca2+ leak.
Under physiological condition, the normal SR Ca2+ leak helps maintain
various cellular functions, such as: 1, gene transcription, a process termed as
excitation-transcription coupling (ETC) (Atar et al, 1995); 2, post-translational
protein modification, a process very critical for cell viability (Anderson et al, 2007,
George et al, 2007); 3, enhancing local regenerativity and reliability of CICR
(Keller et al, 2007; Lindegger et al, 2005); 4, protection by preventing SR Ca2+
overload in some extreme condition like ß-adrenergic over-stimulation (Yang et
al, 2007). Although Zima et al (2010) indicated importance of non-sparkmediated leak and that a complete block of RyR2 can’t totally abolish the leak in
physiology condition, RyR2 mediation is still regarded as the major pathway for
SR Ca2+ leak. RyR2 is normally closed at resting state under low cytosolic
diastolic Ca2+ (~50-100nM). But in pathological states like heart failure and
CPVT, due to pathogenetic modification on RyR2, there is a dramatically
enhanced SR Ca2+ leak, primarily mediated through RyR2 (Shannon et al, 2003;
Maier et al, 2003; Ai et al, 2005; Kohlhaas et al, 2006; Lehnart et al, 2006;
Curran et al, 2007). The patho-physiological role of SR Ca2+ leak can work as 3
primary causes for progressive deterioration in cardiac function: 1, increased SR
Ca2+ leak can work as abnormal Ca2+ signal which is involved in directly inducing
gene transcription leading to hypertrophic remodeling (Frey et al, 2000; Wu et al,
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2006; Molkentin et al, 2006; Mckinsey et al, 2002). 2, Increased SR Ca2+ leak
combined with reduced SR Ca2+–ATPase (SERCA) in HF (Bers, 2001), can
predominantly reduce SR Ca2+ load and impair contractile function(Houser et al,
2000; Pogwizd et al, 2001). 3, Increased SR Ca2+ leak could activate inward
current through Na+/Ca2+ exchanger (Vermeulen et al, 1994), and further evoke
delayed after depolarizations (DADs) and arrhythmogenicity (Pogwizd and Bers
2004; Shannon et al, 2003). All these properties now make RyR2 mediated SR
Ca2+ leak a potential therapeutic target for anti-HF and anti-arrhythmia.
Main mechanisms for enhanced SR Ca2+ leak
1. FKBP12.6 dissociation by PKA phosphorylation
This hypothesis was first proposed by Marx and colleagues (Marx et al,
2000). There are two main supportive points for this theory: (1), FKBP12.6 is the
main stabilizer to keep RyR2 in a fully closed state, and (2), RyR2
hyperphosphorylation at Ser2808 by PKA can dissociate FKBP12.6 from RyR2
causing a leaky state. One of the main features for HF is the chronic
hyperadrenergic state, causing a relatively high plasma catecholamine level and
ß-adrenergic over stimulation. Then PKA can be chronically over activated in a
cAMP-dependent pathway and hyperphosphorylate RyR2 at Ser2808 to
dissociate FKBP12.6 (Marx et al, 2000). Once in the hyperphosphorlated state
that means 3-4 of 4 monomers are phosphorylated, RyR2 loses FKBP12.6
association and could not close completely. So that RyR2 is sensitized to
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cytosolic Ca2+ leading to an enhanced open probability and diastolic SR Ca2+
leak (Lehnart et al, 2004). PKA hyperphosphorylation / FKBP12.6-depletion
theory is supported by other studies about cAMP-specific PDE4D3, a local
phosphodiesterase that could decrease cAMP though negative feedback (Lehart
et al, 2005); PDE4D3 dissociation from RyR can cause elevated cAMP for
chronic activation of PKA and RyR hyperphosphorylation. In some HF models,
RyR2 complex is also found less associated with phosphatases (PP1, PP2a),
which can decrease RyR2 dephosphorylation rate and keep the balance in favor
of hyperphosphorylation (Reiken et al, 2001). Some knock-in mouse model
studies also provide support for PKA hyperphosphorylation theory. In RyR2S2808A knock-in mouse, RyR2 can’t be phosphorylated at Ser2808 and
FKBP12.6 dissociation upon PKA activation is not observed. In post-myocardial
infarction (MI) HF model, RyR2-S2808A mice exhibit stronger resistance to the
progression of HF than wild-type (WT) mice (Wehrens et al, 2006). PDE4D3
knock-out mice also showed cardiomyopathy with hyperphosphorylated RyR2 at
Ser2808 and FKBP12.6 depletion (Lehnart et al, 2005). Furthermore, the direct
genetical depletion of FKBP12.6 showed that this mouse had an increased
propensity for exercise-induced ventricular tachycardia (Wehrens et al, 2003).
But in the past 10 years, this mechanism also met challenges constantly
from other groups for both two main supporting points, focusing on whether PKAmediated hyperphosphorylation at Ser2808 could dissociate FKBP12.6 from
RyR2 and whether FKBP12.6 binding could alter RyR2 gating. Jiang et al (2002)
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found that, in human and canine failing heart, FKBP12.6 exhibits unchanged
binding affinity to hyperphosphorylated RyR2, compared with that from nonfailing heart. In a recent paper, through direct measurement of binding affinity in
permeabilized cardiomyocytes, PKA phosphorylation of RyR2 did not change
binding properties between FKBP12.6 and RyR2 (Guo et al, 2010); the same
study also showed that saturating RyR2 with FKBP12.6 only provides a mild
RyR2 inhibition (~20%), suggesting a small relevance for RyR2 regulation in
cardiomyocytes. Moreover, FKBP12.6 knock-out mice failed to demonstrate
increased arrhythmia propensity by the combination of epinephrine and caffeine,
which is the classical method to induce over SR Ca2+ leak (Xiao et al, 2007).
Knock-in mice (RyR2-S2808A), where RyR2-2808 is nonphosphorylatible, are
supposed to provide cardio-protection for PKA phosphorylation. But this knock-in
mouse failed to produce relevant cardio-protective function to prevent HF
development and progression both in the MI (myocardial infarction) and thoracic
aortic constriction HF animal models (Berkusky et al, 2007; Zhang & Houser,
2012). Piece above information together, PKA hyperphosphorylation and
FKBP12.6 dissociation mechanism is still highly controversial.
2. CaMKII and CaMKII phosphorylation
CaMKII attracted tremendous interest over the last decade in the cardiac
field, because it is broadly involved in ETC and ECC in the heart. In this section, I
am going to briefly review the impact of CaMKII on the whole cardiac system,
especially on ETC and ECC. CaMKIIį is the predominant isoform in heart with
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two subtypes: įB (with a nuclear localization signal [NLS]) localized to nucleus
and įC localized to the cytosol (Maier et al., 2003). CaMK įB has been reported
to be broadly involved in ETC through its modulation of gene expression via
different transcription factors (Zhang and Brown, 2004). For cardiac hypertrophic
growth and gene expression, the Gq/PLC/InsP3 signaling pathway is extensively
studied. In this signaling pathway, NE, PE or ET-1 could affect the expression of
atrial natriuretic peptide (ANF), brain natriuretic peptide (BNP), myosin light
chain-2 (MLC-2), and Į, ß-myosin heavy chain (Anderson, Brown & Bers 2011).
The hypertrophy, caused by those fetal gene expressions, could be prevented by
CaMKII inhibition in neonatal rat ventricular myocytes (Zhu et al, 2000; Ramirez
et al, 1997). CaMKII also can alter cardiomyocyte hypertrophic gene expression
through HDACs and MEF2 signaling. Phosphorylation of class II HDACs
mediated by CaMKII can interrupt MEF2-HDAC interaction resulting in HDAC
nuclear export while free MEF2 for the activation of downstream hypertrophic
gene transcription (Berger et al, 2003; Frey et al, 2000). CaMKIIįc is also
reportly involved in the cardiomyocyte apoptosis via the mitochondria-dependent
pathway. Increased CaMKIIįc activity enhances RyR2 mediated SR Ca2+ leak
and consequently affect mitochondrial Ca2+ and further impacts on expression of
p53 and the pro-apoptotic BAX protein (Zhu et al, 2003 & 2007; Toko et al,
2010). In HF, there is an upregulation of NCX, whose enhanced expression by
ISO was thought had a link to the activation of CaMKII and transcription factor
AP-1 (Mani et al, 2010).
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In ECC, multiple proteins are regulated by CaMKII, including: L-type Ca2+
channel, phospholamban, RyR2, Na and K channels. CaMKII phosphorylates Ltype Ca2+ channel causing a positive staircase of ICaL, representing an increase of
ICa amplitude and prolonged LTCC inactivation over a series of pulses (Yuan et
al, 1994; Xiao et al, 1994). This phenomenon is termed as Ca2+-dependent ICaL
facilitation. Moreover CaMKIIįc can cause modifications of Na channels and shift
the channel availability to more negative membrane potentials, which means
more Na channels can be activated in intermediate inactivated sate (Wagner et
al 2006). This can produce Brugada syndrome like effects (Bers and Grandi
2009). CaMKII also enhances late non-inactivating INa, linked with ischemia /
reperfusion injury, HF and long QT syndrome 3 (LQT3). For K channels, CaMKII
modification can slow transient outward K current (Ito) and accelerate their
recovery from inactivation, both of which can shorten AP duration and refractory
period (Tessier et al, 1999). Over expression of CaMKII is reported to induce
down-regulation of inwardly rectifying IK1, which stabilizes the resting membrane
potential. The reduction of IK1 can increase excitability (Wagner et al, 2009).
Phosphorylation of PLB on Thr-17 by CaMKII can cause a release of PLB
inhibition of SERCA, enhances SR Ca2+ uptake and increases SR load (Mattiazzi
et al, 1994). In HF, the expression and activation of CaMKII are reportedly
increased, resulting in increased RyR2 phosphorylation and diastolic SR Ca2+
leak (Ai et al, 2005). The wildly accepted view is that, RyR2 phosphorylation at
Ser2814 by CaMKII activates RyR2 gating during both diastole and systole (Bers
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& Grandi 2009; Wehrens et al, 2004; Li et al, 1997; Guo et al, 2006). In a knockin mouse of RyR2-S2814D to mimic the RyR2 hyperphosphorilation by CaMKII,
the mutation caused a significantly enhenced diastolic SR Ca2+ leak and
demonstrated increased arrhythmia propensity. While RyR2-S2814A mutants,
where RyR2 can’t be phosphorylated at Ser2814 by CaMKII, shows resistance to
ISO induced arrhythmia (Van Oort et al, 2010). Taken together, it is well
accepted that CaMKII mediated RyR2 Ca2+ leak is one of the major
arrhythmogenic reasons in HF (Chelu et al, 2009).
3. Store Overload Induced Ca2+ Release (SOICR)
Chen and colleagues first proposed this concept based on a phenomenon:
spontaneous Ca2+ release, which is the SR Ca2+ release in absence of
depolarization activating L-type Ca2+ channel (Fabiato et al, 1983; Jiang et al,
2004). Spontaneous Ca2+ release can be observed cellularly in the form of Ca2+
wave, causing a dramatically local and global cytosolic Ca2+ increase. Combined
with NCX, Ca2+ waves can trigger transient inward current and produce DADs.
When the amplitude of DAD reaches the threshold for Na chanel activation, an
action potential can be triggered, leading to triggered arrythmias (Bers 2001;
Pogwizd & Bers 2004). Spontaneous Ca2+ release has a strong dependence on
the Ca2+ load of SR. Some conditions, such as: ß-adrenergic stimulation, digitalis
toxicity, elevated extracellular Ca2+ concentration, and fast pacing, lead to an
increase in SR Ca2+ content to an overload state which can subsequently cause
inappropriate Ca2+ “spillover” (spontaneous Ca2+ release) during diastole. And
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this was termed as store overload-induced Ca2+ release (SOICR) (Xiao et al,
2007).
Since SOICR exhibits a strong link to SR Ca2+ load, it is suggesting that
luminal Ca2+ concentration is the most important trigger for this spontaneous SR
Ca2+ release. This is very different with the CICR, where the cytosolic Ca2+
underlies the activation of RyR2. So the sensor regulating SR Ca2+ release
according to SR luminal Ca2+ is proposed to set a threshold for SR Ca2+ release
(Ching et al, 2000). Diaz et al, (1997) found Ca2+ wave occurring at the threshold
of SR Ca2+ load of ~100 μmol/L cytosol, which is similar to the normal SR Ca2+
content (1~1.5 mmol/L) because SR volume is 18 times smaller than that in
cytosol (Bers 2001). A SR Ca2+ release by Ca2+ wave could decrease SR Ca2+
load by ~15 μmol/L cytosol, which makes SR Ca2+ load fall below threshold
(Bers, 2001). Evidence supports the proposition that activation of RyR2 is
mediated by a luminal Ca2+ sensor that is distinct from cytosolic Ca2+ sensor, but
the molecular identity of this luminal Ca2+ sensor is not yet identified.
Both RyR2 and CASQ2-complex are proposed as primary luminal Ca2+
sensor, and mutations on RyR2 and CASQ2 cause CPVT, characterized by
increased SR Ca2+ leak and DAD triggered arrhythmia. So CPVT provide a very
good model for SOICR study. In Chen’s model, with normal RyR2, the threshold
for SOICR is higher than the free luminal [Ca2+], even in SR Ca2+ overload
condition, so there is none or little Ca2+ spillover. The CPVT mutation in RyR2
can lower the SOICR threshold, but which is still higher than resting luminal Ca2+
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level while below the level of SR Ca2+ in overload state. Thus the increased free
Ca2+ in SR to the overload state, due to catecholamine stress or digitalis
application, can exceed the lowered threshold causing SOICR, while in basal
resting state this will not happen (MacLennan & Chen 2009). For mutations on
CASQ2, two hypothesises are proposed. (1), the mutations, like R33Q or the
reduction of CASQ2, could lower SOICR threshold and sensitize SR Ca2+ release
channel to luminal Ca2+ with the similar effect as RyR2 mutation. (2), the mutation
could reduce the level of CASQ2 and/or Ca2+ buffering capability; this means
that, for the same total Ca2+, the free Ca2+ could be much higher to exceed the
normal SOICR threshold and thereby lead to Ca2+ spillover.
In the bilayer experiments, where the sensitivity of RyR2 to luminal Ca2+
can be gauged, Jiang and colleagues identified some RyR2 mutations that
showed a consistent behavior characterized by an enhanced response of the
channel to luminal Ca2+ activation (Jiang et al, 2004 & 2005). Those mutations
are: L433P and R176Q/T2504M located in the N-terminal region of the channel;
mutations S2246L and R2474S located in the central region; and Q4201R,
N4104K, R4496C, I4867M, N4895D, and V4653F58 located in the C-terminal
region. In summary, SOICR described an aspect of SR Ca2+ leak, the
spontaneous Ca2+ release (Ca2+ wave); the most important consequence is DAD
and triggered arrhythmia; the main reasons for SOICR are RyR2 sensitization to
luminal Ca2+ and enhanced SR Ca2+ load.
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4. Reduction / oxidation (Redox) Modification
The heart is an obligate aerobic organ with the highest oxygen
consumption in the body (Giordano, 2005). As the myocardial O2 level is low,
hypoxia or ischemia could lead to an increased production of redox-active
molecules, which can work as both a benevolent and dysfunctional role to
cardiac system. Redox-active molecules, mainly including reactive oxygen
species (ROS) and reactive nitrogen species (RNS), are widely characterized for
their important role in the cardiac pathologies, especially in ischemia-reperfusion
injury (Zima & Blatter 2006). ROS are the natural byproducts from normal
metabolism of oxygen, which consist of hydroxyl radical (OH.), superoxide (O2-)
and hydrogen peroxide (H2O2). In hypoxia, ROS level can increase dramatically,
therefore cause significant oxidative damage to the cell, which is known as
oxidative stress. Reactive nitrogen species (RNS) are a family of active
molecules mainly derived from nitric oxide (NO) metabolism. Peroxynitrite
(ONOOí) is the main active component and has significant effects with various
biological targets (Khan et al, 2004). Both ROS and RNS can cause protein
alternations mainly by cysteine oxidation. Therefore, in protein oxidative
modification, these two species of redox-active molecules are often collectively
referred to as ROS/RNS. Catalase, glutathione peroxidase and superoxide
dismutase (SOD) are known as the main defense system against this oxidative
damage.
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With 20 active cysteines that could be sensitive to redox modification per
subunit, RyR is a well established redox-modulation channel. Mainly, 3
modifications by redox-active molecules could happen to RyR: (1), the oxidation
through disulfide crosslinking: reagents specifically oxidize two spacially closed
free SH groups and promote the formation of disulfide bonds between two
cysteines within RyR (Eager et al, 1997; Haarmann et al, 1999; Xia et al, 2001);
(2), S-nitrosylation which is the addition of a nitroso group to a sulfur atom of an
amino acid, and (3), S-glutathionylation, the addition of a glutathione molecule to
the amino acid through a disulfide linkage (like protein-SSG). Normally
modifications by low concentration of ROS/RNS are reversible, while high level of
ROS/RNS is able to cause irreversible modifications leading to defective
channels (Ferdinandy and Schulz 2003). In RyR1 several specific cysteines are
already identified for redox-modulation. Cys36 and Cys315 are located at Nterminal region and clamp domain (Liu et al, 2005; Hamilton and Serysheva;
2009 Amador 2009). Cys3635 is located in subdomain 3 which is primary CaM
binding region (Moore et al, 1999; Sun et al, 2001), and S-nitrosylation of
Cys3635 was showed to activate RyR1 by abolishing CaM’s inhibition (Moore et
al, 1999). Oxidized glutathione (GSSG) also shows the ability to increase
channel activity by dissociating CaM binding from RyR2 (Balshaw et al, 2001).
Pathologically, high level nitrosylation to RyR1 has been reported in muscle
dystrophy, and is thought to contribute to muscle weakness by increased SR
Ca2+ leak (Bellinger et al, 2009). For RyR2, the main modification by ROS/RNS is
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oxidation. Those modifications are believed to cause defective RyR2 and
increase SR Ca2+ leak in chronic HF (Terentyev et al, 2008; Belevych et al,
2009). Unlike in RyR1, the specific redox-sensitive cysteine residues on RyR2
have not been identified. Another modification by ROS/RNS is S-nitrosylation
modification, in which S-nitrosoglutathione is required (Sun et al, 2008). Notably,
the high reactive free radicals (like OH. and O2) only have very limited diffusion
range which is within nanometers (Haugland RP, 1996). This implies that ROS
modification

would

be

predominantly

proximal

effect

and

highly

compartmentalized (Zima & Blatter 2006).
5. The interruption of interdomain interaction
Based on the studies about RyR1 and RyR2 related mutations, Ikemoto
and Yamamoto (2002) first proposed this inter-domain interaction concept. Misssense mutations on RyR1 and RyR2 have been found related with two human
inherited diseases: catecholaminergic polymorphic ventricular tachycardia
(CPVT) and malignant hyperthermia (MH) (Brini 2004). The pattern of all known
mutations on RyR is not a random distribution but clustered into 3 major regions:
N-terminal domain (1-600 amino acids), central domain (2000-2500 amino acids)
and channel core forming region (C-terminal domain, 4000-5000 amino acids).
Mutations at either N-terminal or central regions seem to result in similar
sensitization of Ca2+ release channel and leakiness, so they proposed an interdomain interaction concept: after protein folding, N-terminal domain and central
domain could get close in 3D structure and interact with each other to act as a
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regulatory switch for channel-gating. A tight interaction between two domains
serves to stabilize the channel in the full closed “zipping” state; a mutation in
either domain can weaken this inter-domain interaction and cause the channel in
the “unzipping” state (Fig 3b), resulting in channel hypersensitivity and Ca2+
leakiness (Yano & Matsuzaki 2005).
To prove this theory, some synthetic domain peptides are developed for
inter-domain unzipping. In RyR1, DP4 corresponding to the Leu2442–Pro2477 in
central domain, was shown to increase RyR1 open probability by enhanced [3H]ryanodine binding and further induced Ca2+ release from the SR vesicles
(Yamamoto et al, 2000). DP4 also can increase the frequency of Ca2+ sparks in
skinned skeleton fibers, and open probability of RyR1 in bilayer experiment
(Shtifman et al, 2002). The proposed mechanism is that DP4 can insert into the
zipped domain pair causing domain unzipping and channel leakiness (Fig 3b). A
similar cardiac-domain peptide (DPc10) is also synthesized, corresponding to the
Gly2460–Pro2495 in the central domain of RyR2 (Yamamoto and Ikemoto 2002).
DPc10 has been shown to produce significant activation of the RyR2 at low Ca2+
concentrations, which is similar as DP4’s effect to RyR1 (Yamamoto and Ikemoto
2002). In pathological canine HF model induced by rapid RV pacing, Oda et al
(2005) showed the domain unzipping and abnormal Ca2+ leakiness in HF;
furthermore they suggested a possible link between domain unzipping and
FKBP12.6 dissociation. They hypothesized that, in the DPc10-induced domain
unzipping model, the domain unzipping can facilitate both cAMP-dependent
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RyR2 hyperphosphorylation and FKBP12.6 dissociation (Oda et al, 2005).
However, DPc10 induced domain unzipping and SR Ca2+ leaking could happen
with no change to RyR2 phosphorylation and RyR2-bound FKBP12.6 (Oda et al,
2005), which revealed no or weak relation between domain unzipping and
FKBP12.6 binding. Although the relation between PKA phosphorylation / FKBP
dissociation and domain interaction are still not clear, Yano and colleagues think
the domain unzipping is the key mechanism for the destabilization of RyR2 and
Ca2+ leakiness (Yano M, 2006).
With an insertion of green fluorescent protein (GFP) into defined position
in the primary amino acid sequence and followed difference mapping, Liu et al
(2005) showed a physical proximity between N- and central domains in the 3D
structure of RyR2. They also find FRET interaction between these two regulatory
domains in HEK cell with CFP/YFP labeled N- and central domains, However,
the zipping pair (N- and central domains) is not from the same monomer but from
neighbor RyR2 subunits. The treatment of DPc10 (Fig 3c) or caffeine-ryanodine
(Fig 3a) can decrease the FRET interaction causing the unzipping condition in
the visualized method; dantrolene, the effective medication for MH caused by
RyR1 mutation, can prevent the domain unzipping caused by DPc10 insertion
(Liu et al, 2010).
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Fig 3: Domain unzipping. a, domains, in the tightly zipping state, was
unzipped through agonists like high Ca2+ and caffine + ryanodine. b, unzipping
by CPVT mutation. c, unzipping by synthetic domain peptide DPx. (Ikemoto
2002).
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Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
CPVT, a primary electrical myocardial disease without structural cardiac
abnormalities, is characterized by exercise and stress related ventricular
tachycardia which may lead to ventricular fibrillation and sudden death (Priori SG
& Chen SR, 2010). It is thought to affect as many as one in ten thousand people,
and to cause as high as 15% of all unexplained sudden cardiac deaths in young
people (Guy Katz et al, 2009). Bidirectional tachycardia, which is a ventricular
arrhythmia with a 180º alternation for QRS axis (in EKG) on a beat-to-beat basis,
is considered as a typical diagnostic marker for CPVT (Coumel P, et al, 1978;
Priori SG, et al, 2001). But some individuals also have polymorphic VT instead of
a "stable" QRS axis alternation. Mutations on the genes encoding RyR2 and
CASQ2, are currently known to cause CPVT (Priori SG, et al, 2001; Lahat H, et
al, 2001). It is accepted that CPVT requires a synergy between a genetic defect
(i.e., mutation) to sensitize SR Ca2+ release channel, and an external stimulus
(i.e., stress or exercise) which can dramatically increase the SR Ca2+ content for
SR Ca2+ leak. All these conditions working together lead to aberrant Ca2+
release, which consequently activates NCX’s function, generating transient
inward currents and triggering arrhythmias.
CPVT1 is caused by mutations on RyR2 in the autosomal-dominant form.
Now 82 mutations are reported to cause CPVT1; 79 are point mutations and 3
are small deletion/insertion (Priori & Chen, 2010). Those mutations are
considered to confer RyR2 an abnormal gain of function, assumed to cause
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spontaneous Ca2+ release due to altered sensitivity to luminal Ca2+ or / and
cytosolic Ca2+, or increased response to phosphorylation by sympathetic agonist
(Priori & Chen, 2010; Guy Katz & Michael, 2009). These mutations are not
evenly distributed across the entire RyR2 coding region, but clustered into well
defined domains: domain I (amino acid 77 to 466), domain II (amino acid 2246 to
2534), domain III (amino acid 3778 to 4201), domain IV (amino acid 4497 to
4959) (Guy Katz & Michael, 2009). Two mechanisms are proposed for CPVT1.
The First one is FKBP12.6 related; Wehrens et al (2003) first hypothesized that
CPVT mutations could impair FKBP12.6 binding to RyR2 and cause channel
leaking. In bilayer experiments for some CPVT1 mutations on central region
(S2246L, P2328S, R2474S) and C-terminal region (Q4201R, R4494C, V4653F),
they found a common decreased affinity of FKBP12.6 to RyR2 with any those
mutation (Wehrens et al, 2003; Lehnart et al, 2008). However, some studies
found different results that CPVT1 mutations had no effect on FKBP12.6 binding
(Jiang et al, 2005; George CH et al, 2003). So both in HF and CPVT, the role of
FKBP12.6 is highly controversial, at least it won’t be considered as the sole
causative reason for all CPVT1 mutation (Priori & Chen, 2010). The other
alternative mechanism is the so called “domain unzipping” proposed by Ikemoto
and Yano, which was supported by recent RyR2 3D structure study (Amador FJ,
et al, 2009; Lobo PA, et al, 2009; Tung CC, et al, 2010), indicating that most
CPVT mutations are located on the interface of domains where domain-domain
interaction could be disrupted.
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Mutations in the gene for cardiac calsequestrin isoform 2 (CASQ2), can
cause an autosomal recessive form of CPVT (CPVT2). 8 missense mutations are
reported until now. R33Q and D307 are first reported to reduce the level of
CASQ2 to 5% and 45% respectively (Rizzi N, et al 2008; Song L, et al 2007);
along with other missense mutations (K206N, L167H), those four were also
showed to decrease the Ca2+ binding capacity or/and Ca2+–dependent
polymerization of CASQ2 (Rizzi N, et al 2008; Bal NC, et al, 2010; Kirchhefer U,
et al 2010; Valle G, et al 2008). With the same amount of total Ca2+, reduced SR
Ca2+ buffering will result in a fast SR fill-up of free Ca2+ during diastole and
potentially higher level of SR free Ca2+. Both conditions can increase the
propensity for SOICR and consequently DAD. Beside the reduction of SR Ca2+
buffering capacity, R33Q alters RyR2 sensitivity to luminal Ca2+ lowering the
threshold for SR Ca2+ spontaneous release (Qin J, et al 2008; Terentyev D, et al
2008). However, since CASQ2 works as the major intra-SR Ca2+ buffer, the
reduction of CASQ2 protein and Ca2+ buffering capacity is thought the main
mechenism for CPVT2 muatation (Knollmann BC, 2009).
Calmodulin
Calmodulin (CaM) is a ubiquitous and highly conserved Ca2+ binding
protein which regulates multiple cellular processes, such as channel gating, Ca2+
release, and cell cycle progression. With 148 highly conserved residues and
~16.7kDa molecular weight, CaM has two globular Ca2+ binding domains with E-
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F hands, connected by a flexible tether helix (Jurado, Chockalingam & Jarrett,
1999). At high [Ca2+], Ca2+ binds cooperatively to CaM and results in a
conformational change that translate intracellular Ca2+ fluctuation signal to
diverse targets, including more than 30 different target proteins, such as:
phosphodiesterase

(PDE),

myosin

light

chain

kinase

(MLCK),

protein

phosphatase calcineurin (CaN), adenylyl cyclase (AC), nitric-oxide synthase
(NOS), Ca2+-activated potassium channels, Ca/CaM-dependent kinase (CaMK),
L-type Ca2+ channels (LTCC) and RyRs (Means et al, 1991; Vogel et al, 1994;
James P, et al; 1995; Jurado, Chockalingam & Jarrett, 1999; Maier & Bers,
2002). CaM is widely involved not only in EC-coupling by L-type Ca2+ channel
inactivation (Zuhlke et al, 1999; Peterson et al, 2000) and RyR2 regulation, but
also in ET-coupling for hypertrophic signaling transduction especially mediated
through CaMKII. The total cellular CaM concentration is in the range of 2-25 μM,
which varies according to different tissues and species (Kakiuchi et al, 1982). In
cardiomyocytes, the total CaM is about 2-5 μM depending on the species (Maier
2006). It was estimated that, in resting conditions, ~90-95% cellular CaM is
bound to target protein, and free CaM concentration is about 50-75 nM (Wu et al,
2006)
CaM binds to RyR2 stoichiometrically (four CaMs per tetrameric RyR2),
and works as a critical regulator for SR Ca2+ release. The primary CaM binding
region on RyR2 is the residues 3583-3603 (Yamaguchi et al 2003). CaM binds to
RyR in a Ca2+-dependent way. It is proposed that CaM can switch between two
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binding positions on RyR due to oscillating intracellular Ca2+ concentration
(Jurado, Chockalingam & Jarrett, 1999; Samso et al, 2002). However, this
position switch can not be found by FRET measurements (Cornea et al, 2009;
Guo et al, 2011). Mutations to highly conserved CaM-binding region on critical
residues can nearly abolish CaM binding to RyR2. Meissner group bioengineered
a knock-in mouse in which three amino acids in CaM binding region are mutated
(RyR2-w3587A/L3597D/F3603A). This triple-mutation greatly impairs CaM
binding to RyR2 is greatly impaired without interference to other CaM signaling
pathways and lead to severe hypertrophic cardiomyopathy at early stage
(Yamaguchi et al, 2007). In Cryo-EM based 3D RyR reconstruction, Ca2+-free
CaM (apoCaM) binds to a cleft in the cytosolic domain 3 (AA 3614-3643) (Moor
et al 1999; Wagenknecht et al 1994), with a distance of 60-70Å to FKBP12.6 on
the same face of RyR2 (Cornea et al, 2009; Gao et al, 2011). For the functional
meaning, CaM association can inhibit RyR2 activity both for single channel
recording and permeabilized cells. It was reported that CaM could stabilize the
RyR2 in closed state during diastole and could facilitate the termination of Ca2+
release by decreasing the probability of channel reopening, thereby prolonging
the closed time in bilayer experiment (Xu et al, 2004). In permeabilized
cardiomyocytes, increasing CaM binding to RyR2 can decrease Ca2+ spark
frequency by ~70% (Guo et al 2006). In the non-ischemic HF model, CaM
binding affinity to RyR2 and associated CaM was decreased without changing
total CaM, and increasing CaM association to RyR2 can reduce SR Ca2+ leak in
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HF cardiomyocytes (Ai et al, 2005; Ono et al 2010). A recent study indicates that
defective CaM binding to RyR2 is involved in CPVT-associated RyR2 dysfunction
(Xu et al, 2010). Taken together, all these reports suggest that CaM-RyR2
interaction could be a critical molecular substrate for arrhythmias and HF
pathogenic processes.
FK-506 Binding protein
FKBP is a family of intracellular protein named for its binding to
immunosuppressant FK506. Two isoforms of FKBP are expressed in the heart,
FKBP12 and FKBP12.6 (~12 kDa and 108 residues). They are very similar in
sequence (85% homology, 18 residues different) and 3-D structure (Standaet RF
ea al, 1990; Lam E et al, 1995). The main structure of FKBP12/12.6 consists of a
large antiparallel five-stranded, amphiphilic ȕ-sheet which wrapped with its
hydrophobic face against an amphiphilic Į-helix, and thus forms a well-ordered
hydrophobic core, providing a binding site for FK506/Rapamycin (Van Duyne et
al, 1993; Griffith et al, 1995; Huse et al, 1999). Residues 81 to 96 in
FKBP12&12.6 form a small flexible subdomain that interacts with FK506 and
other target proteins (Huse et al 1999; Ke et al 2003). FKBP12 and 12.6 were
found to associate with RyRs primarily and stoichiometrically (i.e., 4 FKBP: 1RyR
tetramer / 1 FKBP12: 1 RyR monomer) (Timerman et al, 1993 & 1996). Guo et al
(2010) described FKBP binding kinetics in permeabilized cardiac myocytes.
FKBP12.6 preferentially binds to RyR2 with very high affinity (Kd=~1nM), while
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FKBP12’s binding affinity is much lower (Kd=~200nM). However, the expression
of FKBP12.6 in mouse cardiac mycytes is low, so that only 10-20% of RyR2s are
associated with FKBP12.6, and the remaining RyRs are associated with FKBP12
(Guo et al, 2010).
The function for FKBP12/RyR1 interaction is well understood, with some
consensus that FKBP12 stabilizes the full conductance state (Brillantes et al.
1994; Ahern et al. 1997), the closed state (Timerman et al. 1993; Gaburjakova et
al. 2001), and coupled gating between neighboring RyR1 channels (Brillantes et
al. 1994; Marx et al. 1998), thus preventing spontaneous channel openings, and
subconductance states. In addition, FKBP12 is proposed to enhance the gain of
EC coupling in skeletal muscle (Lamb et al. 1996; Avila et al. 2003). But in
cardicac myocytes, FKBP12 association to RyR2 could not reduce RyR2 activity
(Ca2+ sparks) (Guo, et al, 2010). A similar role for FKBP12.6 as RyR2 channelstabilizing regulator has been supported by evidence from some groups (Kaftan
et al. 1996; McCall et al. 1996; Xiao et al. 1997; Prestle et al. 2001; Xin et al.
2002; George et al. 2003; Kohno et al. 2003; Yano et al. 2003) but are opposed
by others (Timerman et al. 1996; Barg et al. 1997; Xiao et al. 2007; Jones et al.
2008), so the function for FKBP12.6 as the RyR2 stablizer is still controversial
(reviewed in “Main mechanisms for enhanced SR Ca2+ leak”).
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Fluorescence resonance energy transfer (FRET)
FRET is a phenomenon in which one excited chromophore (donor) can
transfer its excitation energy to a nearby neighbor (acceptor). The energy
transferred between the donor and acceptor is through nonradiative dipole–
dipole coupling (Volkhard 2007), which is a “radiationless” mechanism and
termed "Förster resonance energy transfer". This name is from its discoverer, a
German scientist Theodor Förster. In most cases, the FRET happened between
fluorophores, where the energy transfering can be detected through fluorescence
change. So it is also called "fluorescence resonance energy transfer". There are
two requirements for fluorescence resonance energy transfer (FRET): one is the
spectrum requirement, which is a significant overlap between the donor emission
spectrum and acceptor absorption spectrum; the other one is proximity
requirement, which means the distance between donor and acceptor must be
minimal (usually less than 10nm).
FRET has a broad application for protein studies, especially worked as a
sensitive molecular ruler for an accurate distance measurement between two
labeled proteins and further defining the potential interaction between those two
proteins (LeTilly and Royer, 1993). Another one of most important applications is
to detect conformation changes within a protein complex, in which two domains
are labeled with fluophores. The conformation change can be detected through
FRET efficiency response which reflects the subtle change of two labeling
fluophores’ orientation and distance (LeTilly and Royer, 1993). Additionally,
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FRET is applied for many other studies like: protein sythesis and turnover,
manipulation of protein activity, and monitoring enzyme activity, et al (Giepmans,
Adams, Ellisman, and Tsien, 2006).

CHAPTER III
MATERIALS AND METHODS
Heart Failure Model
In Sprague-Dawley rats, heart failure was induced and developed by
coronary ligation as Tanonaka approach (Tanonaka et al, 2001; Lin et al, 2007).
The rat HF model, developed by Anne Knowlton’s lab (UC Davis), produces HF
in 12 weeks after surgery. The animal protocol was approved by the University of
California, Davis Animal Research Committee in accordance with the NIH Guide
for the Care and Use of Laboratory Animals.
Cardiac myocyte isolation
Isolation of ventricular myocytes was carried out as previous description
(Li et al, 2002). RyR2+/ADA KI mice were provided by Dr G. Meissner (University
of North Carolina). All procedures were performed according to the Guiding
Principles in the Care and Use of the Animals approved by the Council of
American Physiological Society. Hearts were excised from WT or RyR2+/ADA KI
mice, rats (normal and HF). After the animal was anesthetized by 3-5%
isoflurane for 1 min, hearts were excised out and hung on to a Langendorff
perfusion apparatus (37 °C) via aortic cannulation and secured with a stainless
steel alligator clip and tied with silk suture to the cannula. Hearts were perfused
47
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at constant pressure with 0 Ca2+ NT through the coronary circulation for
approximately 5 minutes. This assured that all blood was washed off from the
coronary system. The perfusion solution was then switched to 0 Ca2+ NT solution
containing 0.8 mg/ml collagenase (type B, Boehringer Mannheim) for 7-12 min,
until the heart became flaccid. Hearts were then removed from the perfusion
system and the atria were discarded. The ventricular tissue was chopped into
small pieces and incubated for 10 min at 37qC in a shaking water bath in the
presence of both collagenase and protease. Myocytes were subjected a
dissociation by gentle agitation and filtered through two layers of gauze.
Extracellular [Ca2+] was progressively raised to 1 mM in three successive
washes, each 5 minutes. Myocytes were placed finally in NT solution (in mM):
NaCl 140, KCl 4, MgCl2 1, CaCl2 1, glucose 10, HEPES 5, pH 7.4. All
experiments were performed at room temperature (23 °C).
Cell permeabilization
Cell permeabilization provides a useful tool to control the intracellular
environment and to introduce exogenous agents into cells while keeping relative
intact

cellular

surroundings

(Lukyanenko

and

Gyorke,

1999).

Saponin

permeabilization has been used in intracellular Ca2+ signal recording, such as
Ca2+ spark/wave measurements through confocal microscopy. In this project,
through cell permeabilization, I can keep the [Ca2+]i tightly controlled and prevent
the complication from the L-type Ca2+ channels which localize on the
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sarcolemmal membrane. The potential disadvantage of this method is that some
cellular contents can be lost, which can be partially compensated by experiment
design.
All myocytes originally suspended in NT solution were transfered to
relaxation solution, and then were permeabilized by saponin (50ug/ml). For
fluorescent protein required experiments, myocytes were permeabilized for 3
minutes. For only fluorescent dye required experiments, myocytes were
permeabilized for 20-30 seconds. Relaxation and permeabilization solution
contain (mM): EGTA 0.1, HEPES 10, Kaspartate120, MgCl2 1, ATP 5, reduced
glutathione 10, phosphocreatine di-Tris 5 and saponin 50 ug/ml (only in
permeabilizing solution), pH 7.4. After permeabilization, myocytes were
superperfused with internal solution (mmol/L): EGTA 0.5, HEPES 10, K-aspartate
120, ATP 5; free MgCl2 1, reduced glutathione 10, [Ca2+] 50 nmol/L (calculated
using MaxChelator), creatine phosphokinase 5 U/ml, phosphocreatine 10,
dextran (MW: 40,000) 4%, pH 7.2.
Fluoresent labeling of single-cysteine mutants of FKBP12.6 and CaM
The fluorescent FKBP12.6 and CaM were provided by our collaborators:
Dr Cornea and Dr Fruen (University of Minnesota). The cDNA of the human
FKBP12.6 and CaM were subcloned into the NdeI/NheI site of the pRSET
expression vector (Invitrogen). This hFKBP12.6/CaM clone was used as a sitedirected mutagenesis starting point to create null-Cys FKBP12.6 (C22A/C76I-
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FKBP12.6). Site-directed mutagenesis was carried out on these clones using
quik change site-directed mutagenesis kits (Stratagene). Expression was carried
out in the E. coli BL21 (DE3) pLysS cells, transformed with the mutagenized
hFKBP-pRSET vectors.
Recombinant FKBP/CaM variants were purified by a procedure adapted
from previous reports (Guo et al, 2010). Briefly, the cell lysate was subjected to
40-60 % ammonium sulfate fractionation. The 40-60% pellet was resolubilized in
10-15 ml of 10 mM HEPES (pH 8.0), 1 mM DTT, 0.1 mM PMSF (Buffer A),
dialyzed against 4 L of Buffer A, then subjected to isocratic anion exchange
chromatography on DEAE Sephacel (35 ml gel, 3 cm diameter) pre-equilibrated
in Buffer A. This column was developed with Buffer A at 0.5 ml/min and
FKBP/CaM elutes in the first peak, which was then concentrated to 30 mg/ml,
and NaCl was adjusted to 150 mM. A 1 ml volume of this concentrate was then
applied to a Sephacryl-200 HR (70 x 1.5 cm) pre-equilibrated with Buffer A
supplemented with 150 mM NaCl (Buffer B) at a rate of 0.2 ml/min. Fractions
(1ml) were collected and analyzed by electrophoresis. The fractions containing
>95% pure FKBP/CaM were pooled, and the purity of FKBP/CaM in this sample
was further confirmed by SDS-PAGE. The typical yield was ~30 mg of pure
proteins per liter of cell culture. The concentration of purified WT protein used as
standard was determined by using their calculated extinction coefficients.
The FKBP/CaM mutant was labeled at its single cysteine using the
maleimide derivatives of Alexa Fluor 488 or Alexa Fluor 568. The FKBP/CaM
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sample was treated with TCEP (1mM) for 1 hr in buffer containing 20 mM MOPS,
150 mM NaCl, pH 7.5. The fluorophore was applied then from a DMF stock to a
final concentration of 1.6 mM, DMF was adjusted to 20% by volume, and the
reaction was allowed to proceed for 4 hrs at room temperature, with tumbling,
protected from light. Unreacted dye was removed by chromatography on DEAE
Sephacel and the sample was dialyzed and concentrated using Amicon device
(Millipore, Billerica, MA) into 20 mM MOPS, 30 mM NaCl, pH 7.0 at a protein
concentration of 60-100 µM.
Fluorescence Recovery after Photobleaching (FRAP)
FRAP is a method that can be used to define protein binding kinetics
through optical techniques. First, a protein binding region was photobleached by
strong laser illumination, and then fluorescence recovery of this region is
recorded. The fluorescence recovery in photobleached region is plotted vs time
to yield a curve that reflects the kinetic coefficients for the protein's reversible
binding. Diffusion and binding/unbinding are needed to be considered for the
fluorescence recovery. If the diffusion is very fast and can be ignored in the
whole process, the analysis is very simple since the fluorescence recovery is
determined by the rate at which bleached bound proteins dissociate from their
binding sites and are replaced by free fluorescent protein in the bath. Note that
the recovery depends on dissociation rate (koff) only, not the association rate
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(kon). Some assumptions are necessary for the data interpretation (Bulinski,
2001):

1. The concentration of bound protein region (like Z-line) is much higher than
free protein concentration in the bath, so that the fluorescent contribution of
the free protein can be neglected.
2. There is no significant movement for bound proteins during recovery.
3. Compared with binding/unbinding, the free diffusion is much faster. So that
the contribution of fluorescence recovery by diffusion can be ignored, and
recovery rate reflects the process in which the fluorescent free protein binds
and replaces the bound photobleached protein and so recovers the
fluorescence.

After three assumptions are satisfied, we can fit the recovery curve with single
exponential function and find the on- and off-rate constants for protein binding. In
my experiments, all these assumption are statisfied.

Permeabilized myocytes were incubated with FRET pair: 100nM
fluorescent FKBP12.6 (F-FKBP12.6, donor) and a range of fluorescent CaM [FCaM (acceptor)]s. F-CaM bound on RyR2 was detected through FRET by
sensitized emission. After steady state was reached, F-CaM was photobleached
at Z-lines though 543nM excitation with high laser power (90%) for 50s, resulting
in >95% exposed F-CaM fluophore destruction. Thereafter the patterned striation
recovery of photobleached region was recorded in the FRET acceptor channel
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(488nM excitation, >600nM recording). This reflects recovery of RyR2 bound
CaM through reversible binding, which can be modeled as a first order reaction.
The observed recovery rate constant kFRAP was fitted by a single-exponential
function. The observed recovery rate constant, kFRAP, is an integrated
measurement depending on both kon and koff, which can be described by the
equation:

kFRAP= kon[F-CaM] + koff.
Since kFRAP is F-CaM concentration dependent, measured kFRAP at various [FCaM] allows measurement of kon (slope) and koff (intercept) in a linear fitting (Guo
et al, 2010). Three conditions are important for accurate measurement. 1) There
should be no pre-bound endogenous CaM, which was predepleted by suramin.
2) The initial F-CaM application should be around the ~Kd range. 3) The diffusion
of F-CaM should be much faster than binding/unbinding process, such that it is
not the rate-limiting step.
FRET between F-CaMs and F-FKBP in permeabilized myocytes
For the FRET between FKBP12.6 and CaM, we used fluorescent
FKBP12.6, labeled at position 14 with green-fluorescent Alexa 488 (AF488-14FKBP12.6), and F-CaM labeled with red-fluorescent Alexa 568 attached at the
position 34 (AF568-34-CaM) (Cornea et al, 2009; Guo et al, 2010 & 2011). After
permeabilization, myocytes were placed in internal solution. Fluorescent
FKBP12.6 and CaM were added to the bath solution. F-FKBP12.6 (donor) was
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excited at 488 nm, and emission was recorded through a 500-530nm band pass
filter (donor channel). F-CaM (acceptor for FRET) fluorescence emission was
recorded by sensitized emission through a >600nm filter (acceptor channel). We
utilized two experimental approaches, (1) comparing the donor fluorescence
intensities before and after equilibrating with the acceptor (donor quenching) and
(2) monitoring the increase in donor fluorescence after acceptor photobleaching
(acceptor photobleaching), to detect and measure FRET signals in the
permeabilized cardiomyocytes.
For the donor quenching method, FRET is indicated by a decrease in the
donor fluorescence at wavelengths 500-530 nm (AF488-FKBP12.6), after
acceptor is added and reaches equilibrium. Both donor and acceptor saturate
RyR binding sites. The FRET efficiency is calculated based on the equation:
E = 1 - FDA/FD,
FD is for the fluorescence intensities of the donor-only state, FDA stands for the
fluorescence recorded through donor channel after adding the acceptor.
For Acceptor photobleaching, permeabilized myocytes were first incubated
with AF488-FKBP12.6 and AF568-34-CaM to reach equilibrium. The acceptor
photobleaching was achieved by repeated scans with maximum laser power at
543 nm for 60 sec to completely photobleach the acceptor (AF568-34-CaM).
There is an increase in donor fluorescence signal when FRET is disrupted by
photobleaching of acceptor fluorophore. The FRET efficiency was calculated
according to the equation:
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E = [(Idonor-post – Idonor-pre)/Idonor-post] x 100%,
where Idonor-post and Idonor-pre are donor fluorescence intensity after and before
photobleaching of acceptor fluorescence.
Donor-acceptor distances, R, were calculated from the equation:
R = R0 (E-1-1)1/6,
where the Förster distance, R0 is defined as the distance at which FRET=0.5.
Here R0 for AF-488 and AF568 is 62Å (Invitrogen.com).
Two control experiments are needed for FRET measurement to detect
potential bleeding through or cross talk between donor and acceptor. 1), with
donor alone (AF488-FKBP12.6), acceptor channel whether can detect any signal
due to the excitation of donor. 2), with acceptor alone (AF568-34-CaM), donor
channel whether can detect any signal when acceptors were directly excited
through 543nM laser illumination.
Wash-in/off in myocytes
Fluorescence changes, after a rapid wash-in and wash-off of fluorescent
protein (F-CaM or F-DPc10), can be used to estimate protein binding kinetics in
permeabilized myocytes. After permeabilization, pretreatment was applied to
predeplete possible endogenous bound CaM and made the binding site available
for fluorescent protein. Then I washed in fluorescent protein and recorded the
fluorescence increase in myocytes over time. After the fluorescence reached
steady state, I washed fluorescent protein off by internal solution and recorded
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fluorescence decrease, which was fitted with a single-exponential function. For
wash-off, I can establish koff by fitting the equation: specific-binding = A u exp (koff u t), here A stands for the specific binding (fluorescent value) at equilibrium.
For wash-in experiment, I can fit the association rate constant (kob) by the
equation: specific binding = A u (1 - exp (-kob u t)), from which kon can be
calculated through kob = koff + kon[F-CaM].
Ca2+ signal measurement by fluo-4 with confocal microscopy
1. Ca2+ signal recording in intact myocytes
Ca2+ transients were recorded using 5 µM fluo-4-AM dye loading, a singlewavelength Ca2+ indicator, and the laser scanning confocal microscope (BioRad,
Carl Zeiss).

The confocal microscope is equipped with a 40x oil immersion

objective lens (n.a. = 1.3). Fluo-4 was excited with the 488 nm line of an argon
laser. Emitted fluorescence was collected through a 500-530 nM band pass
emission filter. Fluo-4 images were recorded in the line-scan mode with 512
pixels per line at 166 Hz. Ca2+ transients were obtained by field stimulation at 1
Hz in normal Tyrode’s solution; the amplitude of Ca2+ transient was presented by
F/F0; the time constant was fitted by one exponential; SR Ca2+ load was
assessed by the rapid application of 15 mM caffeine in the normal tyrode (NT).
2. Ca2+ spark measurement and analysis
Ca2+

sparks

were

recorded

in

saponin-permeabilized

ventricular

cardiomyocytes, which were superfused by internal solution with free 50nM /
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100nM [Ca2+]. Sparks were counted and characterized by an algorithm in
Interactive Data Language (IDL 5.3 computer software) (Cheng et al., 1999).
The program detects Ca2+ sparks as areas of increased fluorescence compared
to the standard deviation (SD) of the background of the fluorescence image. We
used the Ca2+ spark measurement threshold 3.8 u s.d., with human verification of
Ca2+ spark detection. Ca2+ spark amplitudes were normalized (F/F0) to
fluorescence baseline (F0). Duration of Ca2+ sparks was taken from the dwell
time at > 50% of the peak level (full-duration-half-maximum, FDHM). Width of
the Ca2+ sparks was indicated by the spatial size at > 50% of the peak level (fullwidth-half-maximum, FWHM). Ca2+ spark frequency (CaSpF) was normalized to
time and spatial size of the volume elements (or voxels) of the cell from which
Ca2+ sparks are measured. It is based on point spread function of the confocal
microscope. Under our conditions (zoom = 3.0), the width and length of one voxel
is 0.2 Pm & 0.2 Pm, and the depth (assumed) is 1 Pm, so the voxel is 0.04 Pm3.
The fluorescence images were recorded in longitudinal line-scan mode (512
pixels per line), such that the volume of one scan line corresponds to 0.04 Pm3
times the number of pixels that are within the cell length.
Statistics
Data are expressed as mean +/- SEM. Significance is evaluated by using
paired or unpaired Student’s t test. One way analysis of variance (ANOVA) was
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used for multiple comparison. P < 0.05 was considered to be statistically
significant.

CHAPTER IV
HYPOTHESES AND AIMS
Cardiac ryanodine receptors (RyR2), intracellular Ca2+ release channels,
play a central role in excitation-contraction coupling (ECC). A dysfunctional
RyR2, exhibiting enhanced diastolic Ca2+ leak, has been implicated in
arrhythmogenesis and heart failure (HF). Excessive diastolic sarcoplasmic
reticulum (SR) Ca2+ leak can reduce SR Ca2+ load and generate cardiac
arrhythmia. Therefore, the RyR2 leakiness regulation (without affecting normal
ECC) is a potentially valuable modality for the treatment of cardiac arrhythmias
and HF. As an important regulator, calmodulin (CaM) binds and stabilizes RyR2.
Single channel studies suggest that CaM inhibits the RyR2 during diastole and
may regulate the shut off of Ca2+ induced Ca2+ release (CICR) during systole.
And defective CaM-RyR2 interaction is broadly implicated in HF and CPVT
models. All these indicate CaM’s essentially patho-physiological meaning for
RyR2 regulation. However, direct measurements of RyR2-CaM interaction in
myocytes are lacking despite its potential clinical importance. My goal here is to
define the physical RyR2-CaM interaction and its functional consequences in
situ. The central hypothesis is that the stoichiometry and degree of RyR-CaM
binding are key determinants in local SR Ca2+ release. Using fluorescent
FKBP12.6 and CaM as well as transgenic mice with defective RyR2-CaM
59
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interaction, I combine FRET and FRAP, Ca2+ sparks measurement, and domain
unzipping peptide (DPc10) to assess both the RyR2-CaM physical interaction
and its functional importance in the native myocyte environment.
Aim 1. Measure the physical in situ binding properties of RyR2-CaM.
CaM has numerous downstream target proteins beside the RyR2, such as
the L-type Ca2+ channel (LTCC), calcineurin (CaN), and Ca2+-CaM dependent
protein kinase II (CaMKII). To minimize interfering nonspecific signals from other
targets, we can use FRET detection to define the RyR2 bound CaM. Studies
indicate that FKBP12.6 and CaM specifically bind to RyR2 in a physically close
enough proximity to produce measurable FRET which is not expected at other
sites. I apply F-FKBP12.6 and F-CaM in saponin-permeabilized cardiac
myocytes and provide original direct measurements of: 1) FRET between CaM
and FKBP12.6 on RyR2 in permeabilized myocytes; 2) RyR2-CaM binding
properties (steady-state affinity, on-& off-rates) from three independent methods;
3) the percentage of Z-line bound CaM is on RyR2 through using knock-in mice,
where a triple-mutation (RyR2ADA) prevents CaM binding to RyR2. The
differences of binding stoichiometry and degree of RyR2-CaM interaction
between WT and knock-in mice would be correlated with functional attributes of
SR Ca2+ release in specific aim 2.
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Aim 2. Define the physiological consequences of RyR2-CaM binding in
cardiac myocytes.
In recent years, CaM has emerged as a critical regulator of SR Ca2+
release. Specifically, CaM helps maintain the RyR2 in a closed state during
diastole and facilitates termination of Ca2+ release by decreasing the probability
of channel reopening and prolonging the closed times. In non-ischemic canine
and rabbit HF models, there is a decreased CaM binding to RyR2 without
changes in total CaM. Based on previously published results and our preliminary
data, I hypothesize that disrupting the RyR2-CaM interaction will lead to aberrant
activation of RyR2 during diastole and systole that could be arrhythmogenic and
contributing to HF. This could be manifested as aberrant diastolic and systolic
Ca2+ release. Using knock-in mice having defective RyR2-CaM interaction
(where interaction with other CaM downstream targets is not affected), I will
measure the diastolic Ca2+ leak in permeabilized myocytes where [Ca2+]i is tightly
controlled, and systolic Ca2+ transient and fractional release in intact myocytes.
The outcome will provide critical new information concerning how RyR2-CaM
interaction influences SR Ca2+ release in myocytes.
Aim 3. Define RyR2-CaM binding affinity in heart failure myocytes.
The affinity of RyR2 binding to both CaM and FKBP12.6 are reported to
be decreased in HF animal model (Ai et al, 2005, Ono et al, 2010). However,
most measurements have been done by using either SR vesicles or cell lysates.
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Here for the first time, we use coronary ligation induced rat HF model to define
RyR2 binding affinity to CaM and FKBP12.6 in situ.
Aim 4. Define CaM as a critical RyR2 stabilizer through RyR2 unzipping
peptide (DPc10).
One hypothesis for elevated Ca2+ leak through cardiac ryanodine
receptors (RyR2) in heart failure (HF) is interdomain “unzipping” that can
enhance aberrant channel activation. A peptide (DPc10) corresponding to RyR2
central domain 2460-2495 mimics this arrhythmogenic RyR2 leakiness by
unzipping N- and central-domains. CaM binds to RyR2 and stabilizes the closed
channel. Little is known about DPc10 binding to the RyR2 and how that may
interact with binding (and effects) of CaM with RyR2. There are 3 small aims to
reveal DPc10 binding kinetics and the relation between CaM and domain
unzipping: 1). DPc10 could bind to RyR2 in a conformation-dependent manner;
2). CaM can prevent RyR2 unzipping caused by DPc10 binding; 3). RyR2
unzipping by DPc10 can decrease CaM binding affinity to RyR2.
All those aims can lead to a better understanding about RyR2-CaM
interaction and functional effects on RyR-mediated Ca release in cardiac
myocytes.

CHAPTER V
Kinetics of Calmodulin Binding to Cardiac Ryanodine Receptors
and Functional Consequences
INTRODUCTION
Approximately 50% of heart failure patients die of ventricular arrhythmia
and sudden cardiac death (Noseworthy & Christopher, 2008). Now it is well
known that RyR2 mediated SR Ca2+ leak could activate inward current through
Na/Ca exchanger and evoke delayed after depolarizations (Vermeulen et al,
1994). In HF there is enhanced diastolic SR Ca2+ leak via RyR2 and other
electrophysiological changes (e.g. up-regulation of NCX) that greatly enhance
the propensity for DADs and triggered cardiac arrhythmias (Pogwizd and Bers,
2002; Bers, Pogwizd and Klaus 2002), which is proved to be the leading reason
for ventricular tachyarrhythmia and sudden cardiac death (Pogwizd & Bers, 2004;
Shannon, Pogwizd and Bers, 2003). Because of RyR2 has emerged as a
potential therapeutic target for treating HF and arrhythmia. Therefore, stabilizing
RyR2 and preventing abnormal Ca2+ leak (without affecting normal excitation
contraction coupling) is a potentially valuable modality for the treatment of
cardiac arrhythmias and HF.
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Calmodulin is a very important RyR2 regulator, but also has many cellular
binding partners involved in different cellular processes. With 148 highly
conserved residues, CaM has two pairs of globular Ca2+ binding E-F hand
domains connected by a flexible tether helix (Jurado, Chockalingam and Jarret,
1991). At high [Ca2+], Ca2+ binds cooperatively to CaM and result in
conformational change that translate intracellur [Ca2+] signals to diverse targets,
including: myosin light chain kinase (MLCK), protein phosphatase calcineurin
(CaN), nitric-oxide synthase (NOS), phosphodiesterase (PDE), adenylyl cyclase
(AC), Ca2+/CaM-dependent kinase (CaMK), Ca2+-activated potassium channels,
L-type Ca2+ channels (LTCC) and RyRs (Means et al, 1991; Vogel 1994; James
et al, 1995; Maier and Bers, 2002).
CaM binds to RyR2 stoichiometrically (four CaMs per tetrameric RyR2),
and works as a critical regulator for SR Ca2+ release. Cryo-EM based 3D RyR
reconstruction showed that Ca2+-free CaM (apoCaM) binds to a cleft in the
cytosolic domain 3 (AA 3583-3603) (Yamaguchi et al, 2003), with a distance of
60-70Å to FKBP12.6 bound to the same RyR2 face (Moore et al, 1999;
Wagenknecht et al, 1994), and FRET can occur between these two partners
(Cornea et al, 2009; Guo et al, 2011). FKBP12.6 was reported to bind RyR2
tightly as an important regulator in RyR2 gating but some aspects are still
controversial (Brillantes et al, 1994; Marx et al, 1998; Barg et al, 1997; Guo et al,
2010). It was reported that CaM could stabilize the RyR2 in closed state during
diastole and could facilitate the termination of Ca2+ release by decreasing the
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probability of channel reopening and prolonging the closed time (Xu et al, 2004).
Additionally, defective RyR2-CaM interaction has potentially broad implication in
cardiac pathology. Mutations of critical residues in the highly conserved CaM
binding region can severely abolish CaM binding to RyR2 and cause severe
hypertrophic cardiomyopathy and early death in animal models (Yamaguchi et al,
2007). In non-ischemic HF animal models, CaM binding to RyR2 was decreased
(Ai et al, 2005; Ono et al, 2010). A recent study indicates that defective CaM
binding to RyR2 is also involved in CPVT-associated RyR2 dysfunction (Xu et al,
2010). All these studies suggest that CaM-RyR2 interaction is a critical molecular
substrate for arrhythmias and HF pathogenesis.
However, due to its multiple binding targets, CaM-RyR2 binding affinity is
measured in isolated systems, SR vesicles, lipid bilayers or cell lysates, rather
than in native cells. Here by using FRET, we can identify RyR-bound CaM vs its
numerous other target proteins, and for the first time we characterize CaM-RyR2
interaction properties both for the normal and HF cardiomyocytes in the native
cellular environments. The knock-in mice (RyR2+/ADA) (Yamaguchi et al, 2007),
with genetically disrupted CaM-RyR2 association while the interaction with other
CaM targets are not affected, are used to estimate the percentage of Z-line
bound CaM that is on RyR2, and further define pathophysiological consequences
of CaM for RyR2 regulation in cardiomyocytes.
MATERIALS AND METHODS
Pretreatment with suramin to predeplete bound endogenous CaM.
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In resting cardiomyocytes, endogenous CaM is already prebound to most
binding sites. We used suramin to predeplete endogenous bound CaM and make
binding sites accessible for F-CaM, allowing accurate measurement of association kinetics. After myocytes permeabilization, suramin (5μM) was applied for
5min, and then followed the wash-off with internal solution for 20 min.
FRET measurement for F-FKBP12.6 and F-CaM on RyR2 in permeabilized
myocytes.
See details in chapter III
FRET + steady-state concentration -dependent CaM binding in myocytes.
Myocytes were first superfused with relaxing solution, and then
permeabilized with saponin. Once permeabilized, myocytes were incubated with
5 μM suramin solution for 5min to predeplete endogenous bound CaM and then
washed for 20min by internal solution. Then 100nM AF488-FKBP12.6 was
washed in to saturate FKBP binding site on RyR2. After that AF543-CaM in
different concentrations was washed in, with binding allowed to reach steady
state. Excitation wavelengths is 488 nM for FRET and 543 nM for direct Z-line
CaM measurement. For FRET, emission is recorded at 500-530nM for donor
channel and >600nM for acceptor channel. Thus we have two sets of
measurements, one for CaM binding at the Z-line (direct fluorescence) and one
that is specific for RyR2 bound CaM (FRET).
In situ FRET + FRAP, to measure kon & koff for CaM-RyR2 interaction.
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Permeabilized myocytes are incubated with 100nM F-FKBP12.6 and a
range of [F-CaM]s, each until steady state is reached. Z-line bound F-CaM will be
photobleached by 543nM excitation with high laser power (90%) for 50s,
resulting in >95% fluophore destruction. Thereafter the recovery of striation
pattern in photobleached region is recorded through the FRET acceptor channel
(488nM excitation, >600nM recording).
FRET + wash-in/off for the measurement of kon and koff for CaM-RyR2
interaction.
FRET fluorescence changes were monitored in rapid wash-in and washoff of F-CaM in permeabilized myocytes. After pretreatment with suramin, the
permeabilized myocytes were first saturated with F-FKBP12.6 (100 nM). This
gave a strong striation pattern in the donor channel. While keeping RyR2
saturated with F-FKBP12.6, F-CaM was washed in and the fluorescence
changes over time in both donor and acceptor channel were recorded. After the
fluorescence reaching steady state, F-CaM was washed out with keeping RyR2
saturated with F-FKBP12.6 (with excess non-fluorescent CaM to prevent
rebinding of F-CaM), and the fluorescence got recorded in acceptor channel.
Confocal Ca2+ imaging
Ca2+ sparks were measured as a readout for diastolic RyR2 activity in
saponin-permeabilized (20-30 seconds) ventricular cardiomyocytes, which were
superfused by internal solution with free 50nM/100nM Ca2+. For details see
section III.
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For systolic RyR2 function test, intact ventricular myocytes were loaded
with Fluo-4 AM (5 ȝM, Molecular Probes) and Ca2+ transients were recorded as
previously described (Van Oort et al, 2010). Ca2+ transients were obtained by
field stimulation at 1 Hz in normal Tyrode’s solution. SR Ca2+ load was evaluated
by Ca2+ transient upon rapid caffeine application (10 mM). Experiments were
performed on a confocal microscope (BioRad, Radiance 2100, 40x objective) in
line scan mode with argon laser (Ȝex 488 nm, Ȝem >505 nm). Image analysis
was done with ImageJ, Ca2+ spark master and custom made software
implemented in LabVIEW® (National instrumental Ive).
Heart Failure Model
In Sprague-Dawley rats, heart failure was induced and developed by
coronary ligation describled as the approach of Tanonaka (Tanonaka et al, 2001;
Lin et al, 2007). The rat HF model, developed by Ann Knowlton’s lab (UCD),
produces HF in 12 weeks after surgery.
RESULTS
Predepletion of endogenous CaM by suramin
RyR2s are concentrated along the Z-line, and previous studies showed
that CaM is highly concentrated within the same Z-line region and >90% apoCaM
binding sites are occupied by endogenous CaM (Wu et al, 2007). Fig 4A(i) shows
the striation image of fluorescent CaM (F-CaM) concentrated on Z-line, after
60nM [F-CaM] was washed in. Suramin (5μM) can totally abolish the striations
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within 1 min (Fig 4A (ii)); after the wash-off of suramin, F-CaM can rebind at the
Z-line with the same striation pattern (Fig. 4A (iii)). Before suramin treatment, FCaM washed in and yield a moderately slow increase of F-CaM fluorescence at
the Z-line (W = 11.5 min, Fig. 4B). This slow phase represents F-CaM replacing
endogenous bound CaM (Wu et al, 2007). After suramin depleted F-CaM binding
and was washed off for 20 min (hydrophilicity allows rapid reversibility), F-CaM
rebinds much faster at Z-line (Fig. 4C). Now F-CaM striations appeared with Wfast
= 2 min, which represents the time constant for F-CaM binding to unoccupied
binding sites at Z-line. Since Bmax before and after suramin treatment are the
same, we think suramin may completely deplete endogenous CaM bound at Zline which are then totally washed off.
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Fig 4: Suramin can predeplete endogenous CaM. A, confocal
images of saponin-permeabilized myocytes incubated with 60nM F-CaM in
different conditions. (i), after 40min incubation, fluorescent striations reached
Bmax. (ii), 10uM suramin can totally abolish fluorescent striations within 1 min.
(iii), after suramin treatment and rewash-in F-CaM, fluorescent striation
reached Bmax much faster. B, time course for 60nM F-CaM wash-in,
immediately after permeabilization. C, time course for 60nM F-CaM rewashin, after suramin treatment.
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FRET between FKBP12.6 and CaM on the RyR
Both CaM and FKBP12.6 bind RyR1 at a very close proximity and get
FRET interaction (Cornea et al, 2009). In cardiac myocytes CaM and FKBP12.6
are concentrated at the Z-line (Guo et al, 2010; Xu et al, 2007). Here, using
acceptor photobleach, we investigate the efficiency of FRET pair (F-FKBP and FCaM) which reflects the distance between these two proteins on RyR2 in cardiac
myocytes. After F-FKBP12.6 and F-CaM are preequilibrated, we observed
striation both at donor channel (green, Em = 500-530 nM) and acceptor channel
(red, Em > 600 nM). Acceptor (F-CaM) was selectively photobleached by
powerful 543nM excitation in the central region, while the donor fluorescence got
enhanced only in this region (Fig 5A). The average FRET efficiency is 0.35 ±
0.04 (n=8) reflecting a distance of 69 ± 0.7 Å (Fig 5B) between this FRET pair,
which matches well with the result on RyR1 (Cornea et al, 2009). As a valuable
control, repeating the photobleaching with only AF488-FKBP12.6 present had no
effect on donor emission (Fig. 5C). Based on a RyR1 EM-model, the distance
between FKBP and ApoCaMs on the same side of RyR is 50-60 Å (Samso et al,
2002), which is well within the FRET range (10-100 Å). The distance between
FKBP12.6 and CaMs on other RyR faces could be: R2=122 Å, R3=232 Å and
R4=207 Å (Fig 5D), which are all out range of FRET with respect to AF488 and
AF568 (R0 = 62 Å). Therefore, we think 69 ± 0.7 Å is the distance for the same
side FKBP12.6 and CaM, and there is no possibility of FRET interference from
the other side of RyR2.
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Fig 5: FRET between F-FKBP12.6 (donor) and F-CaM (acceptor)
in permeabilized rat myocytes. A, permeabilized myocytes were
incubated with 100nM F-FKBP12.6 and 1uM F-CaM to reach steady-state.
After acceptor photobleaching, there is a fluorescence enhancement in
donor channel. B, the average FRET efficiency and reflected distance for FFKBP12.6 and F-CaM on RyR2. C, acceptor photobleaching had no effect
on donor emission. D, based on RyR1 EM-model, the distance between FFKBP and F-CaM on the same face of RyR (R1) is 50-60Å (Samso et al,
2002); the distances to other side potential FRET partner (R2, R3, R4) are
out of FRET range.
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Measurement of binding affinity (Kd) of CaM-RyR2
The strong FRET interaction between F-FKBP12.6 and F-CaM provides
us with an effective approach to distinguish CaM bound to RyR2 vs other CaM
binding partners (Guo et al, 2011). After suramin pretreatment, 100nM AF488FKBP12.6 (donor) first was washed in to saturate FKBP binding site on RyR2
(Guo et al, 2011), then AF543-CaM (acceptor) at different concentrations was
washed in, with binding allowed to reach steady state. The RyR2 bound CaM can
be detected through FRET by sensitized emission, where excitation wavelengths
is 488 nM for FRET measurement and emission is recorded at 500-530nm for
donor and >600nm for acceptor. Fig. 6A shows the fluorescent cross striation
pattern at 2 different [F-CaM]s in both donor channel (green, Em= 500-530nm)
and acceptor channel (red, Em>600nm). With high [F-CaM] there is a reduced
donor and an increased acceptor (FRET) signal. In the acceptor channel, the
heights of the FRET signal peaks (difference between Z-line and M-line)
represent the amount of CaM specifically bound to RyR2, which are well fitted
with single specific binding curve with Kd=18.2 ± 2 nM (Fig 6B). To test whether
these FRET measurements reflect 1:1 transfer betweent F-CaM and FFKBP12.6, we plotted the donor fluorescence change upon acceptor binding
increase. A linear relationship reveals a 1:1 ratio for donor and acceptor (Fig 6C).
Thus the source of FRET appears to be exclusively between FKBP12.6 and CaM
bound to the same face of the RyR2 (e.g. not on anther nearby protein).
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Fig 6: Kd for RyR2 bound CaM. A, the FRET images for 2
different acceptor [F-CaM]s, while keeping the donor saturated. There is a
decreased donor signal but increased signal acceptor for high [F-CaM]
incubation. B, signal in acceptor channel was fitted with single saturable
binding revealed the binding affinity for CaM-RyR2 (n=11-13). C, the
donor fluorescence decreased upon the acceptor binding, a linear
relationship revealed a 1:1 donor and acceptor ratio (n=11-13).
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Since in FRET the fluorescent energy transferred between donor and
acceptor, and the ratio of donor and acceptor is 1:1, then we can fit the Kd value
from both donor and acceptor signals. We plotted the mean fluorescence value
of donor or acceptor fluorescence versus CaM concentration. The acceptor
fluorescence was fitted by equation:
F(acceptor) = Bmax x [CaM] / (Kd + [CaM]), Kd = 18.2 nM (Fig 7)
And donor fluorescence was fitted by equation:
F(donor) = C – Bmin x [CaM] / (Kd + [CaM]), C stands for the donor max
fluorescence without the acceptor, and Kd = 19.4 nM (Fig 7)
We can see that both Kd values fitted from the donor and acceptor signals are
very similar, testing that the Kd value is correctly estimated.
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Fig 7: Kd fitting from both donor and acceptor signals. C is the max
donor fluorescent value without the acceptor.
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Furthermore, by using direct 543nm F-CaM excitation (not FRET), we
measured the Kd for Z-line total CaM (CaM bound to RyR2 plus other sites along
the Z-line). Fig 8A shows the Z-line striated pattern by direct excitation at
different [F-CaM]s. Similarly, the plot of peak height reveals a single saturable
binding component for F-CaM at the Z line with the Kd of 17.2 r 1.8 nM (Fig. 8C).
The Kd values for RyR2-CaM and Z-line CaM are very close. One possible
explanation is that RyR2 is the quantitatively dominant CaM binding site in the Zline. The other is that several CaM binding sites have almost the same apparent
affinity. Through linear bath [F-CaM] calibration (Fig 8B), we can infer the
concentration of Z-line bound F-CaM in permeabilized myocytes. The CaM (Bmax)
reflects the total amount of binding of CaM on Z-lines,(1.2 μM). These CaM
binding values are similar to our prior work (Song et al, 2009) and consistent with
FKBP12.6 binding in rat myocytes (Guo et al, 2010.
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Measurement of binding kinetics of CaM-RyR2
Measurement of kon and koff for CaM-RyR2 by FRET + wash-in/off in
myocytes. After pretreatment with suramin, the permeabilized myocytes are
saturated with F-FKBP12.6 (100 nM). Using FRET, we can characterize CaMRyR2 association (kon) and dissociation (koff) rate in wash-in/off experiment. Fig
9A illustrates a representative time course of FRET intensity in the 20nM [F-CaM]
continuous wash-in/off experiment. For wash-off, the fluorescent striation pattern
gradually declined and followed the single exponential decay with a time constant
of 4.5 min, which means koff = 0.22 ± 0.01 min-1 (n=5). For wash-in, the
association rate is dependent on the on-, off-rate and [F-CaM] (kwashin = kon [CaM]
+ koff). Since kwashin can be fitted, we can calculate kon =18.9 ± 1.6 x 106min-1M-1
(n=5). Based on kon and koff, Kd can be calculated (Kd = koff / kon = 12 ± 0.9 nM),
and is consistent with the result from the steady-state binding experiment.
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Fig 9: CaM-RyR2 on- & off-rate measured by FRET + washin/off (n=5). Representative time course of FRET CaM fluoresence
intensity in 20nM [F-CaM] continuous wash-in/off.
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Using FRET + in situ FRAP, to measure kon & koff for CaM binding to RyR2
in myocytes. Permeabilized myocytes were first equilibrated with saturating FFKBP12.6 (100nM) and [F-CaM] in Kd range. After photobleaching the acceptor
by 543nM excitation, there is a recovery of photobleached striation pattern. The
recovery of FRET allows a measurement of RyR2-bound CaM recovey rate
(kFRAP). This recovery reflects reversible CaM-RyR2 binding, in which the
photobleached RyR-bound F-CaM was replaced by fresh F-CaM from the bath.
Fig 10A shows the recovery of FRET in 20nM bath [F-CaM] at different times. In
Fig 10B, kFRAP was fitted by single-exponential function in two different bath [FCaM]s, on which the fluorescence recovery is dependent. According to the
equation: kFRAP= kon[F-CaM] + koff, kon (slope) and koff (intercept) were fitted by
linear regression (Fig 10C). Both kon = 14.5 ± 2.5 x106 min-1 M-1 and koff = 0.144 ±
0.05 min-1 agree well with wash-in/off experiment, and calculated Kd = 10 ± 2 nM
also matches results above.
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Estimating the percentage of Z-line total CaM that is RyR2-bound
Knock-in mice with genetically disrupted CaM-RyR2 interaction are used
here (along with WT mice) to test the percentage of Z-line total CaM that is due
to RyR2, vs other CaM binding targets, like LTCC. These knock-in mice express
RyR2 with a triple-mutation (RyR2-W3587A/L3597D/F3603A), where the binding
of CaM to RyR2 is dramatically impaired without interfering with other CaM
signaling pathways (Yamaguchi et al, 2007). Notably, these mice, when
homozygous, die very soon after birth; however the heterozygous mice survive
long enough to be useful experimental animals (Yamaguchi et al, 2007). In
steady state binding, we detect a decrease both for CaM binding on RyR2 by
FRET, and Z-line total bound CaM by direct F-CaM exitation (Fig 11A, B). For
RyR2ADA/+, there is a 50% reduction in the FRET with unchanged binding affinity
(Fig. 12A), which fits the expectation that in heterozygous mice 50% RyR2
monomers have the triple-mutation. But for the Z-line total CaM, there is a 46%
reduction (Fig. 12B), which is due to 50% decrease in CaM binding to RyR2. This
means ~92% of Z-line localized CaM is on RyR2. In control experiments (Fig 13
A & B), we tested that the total binding (Bmax) of FKBP12.6 to RyR2ADA/+ and WT
myocytes is unchanged, indicating that the total number of RyR2 monomers is
the same, which matches previous [3H] ryanodine binding experiments in these
mice (Yamaguchi et al, 2007).
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Fig 11: Confocal images for RyR2 bound FRET CaM and Z-line
bound total CaM (RyR2ADA/+ vs WT). A, FRET images in saturating
condition for WT and RyR2ADA/+, Bmax (FRET CaM) decreased for
RyR2ADA/+ mutant. B, Z-line total bound F-CaM images for WT and
RyR2ADA/+.
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Fig 12: Percentage of Z-line CaM that is bound to RyR2. A, for
RyR2ADA/+ in steady state binding, Bmax (FRET CaM) decreased ~50% with
a similar Kd compared with WT (n=12-20). B, for Z-line bound total CaM in
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86

A

FKBP12.6 Binding (A.U)

B

WT

ADA/+

40

20

0

WT

ADA/+

Fig 13: Total binding (Bmax) of FKBP12.6 for WT and RyR2ADA/+
mice. A, The confocal images of F-FKBP12.6 binding for WT and
RyR2ADA/+. B, Bmax (100nM) is the same for RyR2ADA/+ and WT (n=20).
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Ca2+ sparks in permeabilized RyR2+/ADA KI mouse myocytes
Saponin-permeabilized myocytes are powerful tools for the evaluation of
diastolic SR Ca2+ leak. Through cell permeabilization, we can tightly controll the
[Ca2+]i and prevent complications from L-type Ca2+ channels which also can
trigger RyR2 mediated Ca2+ release. However, the potential disadvantage of this
method is that some cellular contents (like endogenous proteins) can be lost due
to wash-off. Since the endogenous CaM associated with RyR2 may be washed
off within 5 min (Fig 9A), we modified the permeabilizing protocol for Ca2+ spark
measurement to partially compensate this disadvantage. For the Ca2+ spark
measurement here, myocytes were exposed to 50μg/ml saponin for only 20-30 s’
instead of the 3 min used above for CaM wash-in. Fig. 14 shows that after 20-30
s’ permeabilization, Ca2+ sparks were detected in myocytes after 20 min
exposure to F-FKBP12.6, F-CaM and fluo-4. In this case there is no visible
striated pattern abservable for F-FKBP12.6 or F-CaM or FRET. This indicates
that fluo-4 can enter the cell but that CaM and FKBP12.6 can not. For the 3 min
permeabilization, both FRET striation pattern and Ca2+ sparks were detected
indicating that all 3 probes entered the cell. This experiment indicates that 20-30
s’ permeabilization can effectively prevent FKBP12.6 and CaM wash-off during
the time of Ca2+ spark measurement. Thus, we can make Ca2+ spark
measurement in the relatively native cellular environment with respect to CaM
and FKBP12.6 presence.
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Fig 14: Effect of different time permeabilization. A, 30 sec
permeabilization only fluo4 can enter the cell. B, 3 min
permeabilization can make F-FKBP12.6, F-CaM and fluo4 enter the
cell.
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Using this approach, we evaluated diastolic SR Ca2+ leak by recording
Ca2+ sparks within 15-20 min after permeabilization. Fig 15A-B shows that, at
baseline ([Ca2+] = 50nM), Ca2+ spark frequency was significantly increased in
RyR2+/ADA mice versus WT (8.85 ± 0.26 vs 6.4 ± 0.51 /s per 100 μm), while SR
Ca2+ content appeared slightly but insignificantly decreased for RyR2+/ADA
mutants (Fig 15B). The increase of Ca2+ spark frequency could not be inhibited
by AIP, the specific CaMKII inhibitor (Fig 15B). This is consistent with the
reduced CaM binding to RyR2 allowing higher RyR2 activity, and rule out the
potential contribution of CaMKII activity to this observation. Ca2+ spark properties
(Ca2+ spark amplitude, full duration at half-maximum, full width at half-maximum,
and maximum Ca2+ release) were unchanged (Fig. 16). Then we increased
intracellular [Ca2+] slightly to 100nM, close to the threshold for Ca2+ wave
production, to further test the propensity for DADs or arrhythmogenesis. The
increased [Ca2+] mimics a Ca2+ loading stress in permeabilized cells, since both
cytosolic and SR Ca2+ load are increased. We can see that for RyR2+/ADA mutant
mice ~90% of myocytes produced Ca2+ waves, but for WT mice only ~10% of
myocytes produce Ca2+ waves (Fig 15C, D) while no significant difference in Ca2+
SR load was detected (Fig 15D). All these data indicate that the ADA mutation in
RyR2, which caused CaM dissociation from RyR2, increases diastolic SR Ca2+
leak under resting conditions and leads to a significantly higher propensity for
arrhythmogenic Ca2+ wave production under moderate Ca2+ loading condition.
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Ca2+ transients for RyR2+/ADA KI mouse in intact myocytes
We also measured Ca2+ transients in intact ventricular myocytes (Fig 17A)
with or without isoproternol (ISO, 50 nM) present, and SR Ca2+ content was
evaluated through rapid caffeine application. In 1 Hz field stimulation for the
basal level, the myocytes from RyR2+/ADA mutant behave as WT in Ca2+ transient
amplitude, time constant of Ca2+ transient decline, SR Ca2+ content and fractional
SR Ca2+ release (Fig 17B-E). However, exposure to 50nM ISO revealed
differences including prolonged time constant of Ca2+ transient decline,
decreased SR Ca2+ content and increased fractional SR Ca2+ release (Fig 17CE). At the same time, for the RyR2+/ADA mutant, there is a major increase of
propensity for Ca2+ wave and triggered activity under ISO conditions (Fig 18).
Indeed, the induction of Ca2+ waves that can trigger action potential in the
presence of ISO indicates significant arrhythmogenic risk when CaM binding to
RyR2 is inhibited. With Ca2+ loading via 50nM ISO, in RyR2+/ADA KI myocytes, the
highly sensitized RyR2 can contribute to the prolonged Ca2+ transient decline,
SR Ca2+ depletion and higher fractional release, but resulting in relatively normal
Ca2+ transient amplitude ( similar as WT).
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Binding affinity (Kd) of CaM/FKBP12.6 to RyR2 in HF myocytes.
To further examine the CaM binding affinity under a pathological condition,
we measured the CaM-RyR2 binding affinity in a rat HF model induced by
coronary ligation. In this rat HF model, HF developed in 12 weeks post-surgery.
In this HF model an increased heart/body weight ratio, increased LV diastolic
dimensions (LVDD) and decreased fractional shortening were observed (Lin et
al, 2007). Other HF molecular markers, like ANP, BNP, and TNF-Į were also
found significantly increased in this HF model (Lin et al, 2007). Here we only
used HF rats with LVDD > 1.1 cm (normal: 0.9) and fractional shortening < 20%
(normal: 43%) for experiments. Through FRET detection and steady-state
concentration-dependent binding, the Kd for CaM-RyR2 measured in HF
myocytes is 50.9 ± 4.4 nM (Fig 19A). Compared to the Kd for normal myocytes,
there is a ~3 fold decrease in CaM affinity for the rat HF model. To exclude the
possible strain/species difference, we performed additional control experiments.
We tested the CaM-RyR binding in control vs HF rats in the Kd range of [CaM]
and at saturating [CaM] (Bmax) (Fig 19C). In the Kd range, which is sensitive to
detect affinity changes, we see a significant decrease in CaM binding to RyR2 for
HF myocytes, indicating a decreased binding affinity, but unchanged Bmax for
CaM binding. FKBP12.6 has been suggested to also be a critical RyR2 stabilizer
whose affinity changes in HF, despite the intensive controversy (Bers, 2012).
We, for the first time, examined the FKBP12.6-RyR2 binding in situ affinity in HF
myocytes. Through steady-state binding measurement, the Kd for FKBP12.6-
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RyR2 is 0.84 ± 0.07 nM (Fig 19B). This is almost unchanged in comparison to
our previous control Kd value (Kd = 0.7 ± 0.07nM measured in the same
conditions (Guo et al, 2010)). To more careful test for differences, the same
paired control experiments as done for CaM were performed. Fig 19D shows that
FKBP12.6 binding was unaltered when [FKBP12.6] was in either the Kd range or
saturating condition in control vs HF rat myocytes.
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Fig 19: Kd for CaM/FKBP12.6 binding to RyR2 in HF myocytes. A,
Using FRET detection (as in Figure 1) and steady-state binding isotherms, we
measured an increase in the Kd (decrease in affinity) of CaM-RyR2 binding in
HF myocytes, but we detected no significant change in the FRETmax. B,
Using direct excitation of FKBP12.6, and steady-state binding isotherms, we
detected no significant differences in the FKBP12.6-RyR2 binding in HF and
normal myocytes. C, At sub-saturating [A-CaM] (§Kd), there is a significant
decrease in CaM bound to RyR2 in HF myocytes, but there is no significant
change in FRETmax (at saturating A-CaM). D, for Kd range or saturated
condition (Bmax), the FKBP12.6-RyR2 associate rate are unchanged for
normal and HF myocytes
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DISCUSSION
In this study through fluorescent protein and FRET detection, we for the
first time identify CaM bound to RyR2 vs its other targets and characterize CaMRyR2 interaction properties (Kd and on/off rates) in permeabilized ventricular
myocytes by 3 independent methods (Table 1). The knock-in mice, with
genetically disrupted CaM-RyR2 association but no effects on other CaM binding
targets, are used to estimate the percentage of Z-line CaM that is bound to
RyR2. And the patho-physiologically functional consequences of CaM for RyR2
regulation are defined through confocal Ca2+ measures at myocytes in RyR2ADA/+
KI mice. We further define the in situ CaM-RyR binding affinity in HF myocytes to
reveal a potential pathological role of reduced CaM binding in RyR2 regulation.
All these results could lead to a crucial improvement for understanding and
definition of CaM-RyR2 interaction in cardiac myocytes in health and disease.
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Table 1. Summary of CaM-RyR2 binding properties

kon (x106min-1M -1)

koff (min-1)

Kd (nM)

Wash-in/off

18.9 ± 1.6

0.22 ± 0.01

12 ± 0.9

FRAP

14.5 ± 2.5

0.144 ± 0.05

10 ± 2

--

--

18.2 ± 2

Steady-state
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CaM-RyR2 binding properties in the myocytes
CaM, as an important RyR2 regulator, may be important in HF, cardiac
hypertrophy and CPVT. But CaM-RyR2 in situ binding properties are unknown.
Through 3 independent methods, we showed that CaM can bind to RyR2 with
high affinity (Kd = 10-20 nM) in resting condition, where [Ca2+]i is 50nM. In this
condition, according to the measured free [CaM] in myocytes (50-75 nM) (Wu X,
et al, 2007), ~70-90% of RyR2 monomers are associated with CaM, which
makes CaM a potential important RyR2 stabilizer, because CaM is associated
with the majority of RyR2 monomers and inhibits RyR2 opening at all
physiological [Ca2+]. Our measured binding affinity is higher than the result from
cell lysates and SR vesicles (Guo et al, 2011; Ono et al, 2010). We think that
could be due to differences of experiment conditions. In lysates and SR vesicles
experiments, there is a higher risk of losing essential partners from the cellular
environment or causing subtle modification to RyR2 (such as: phosphorylation or
oxidation). And phosphorylation, oxidation, or conformation change can
dramatically decrease CaM-RyR2 binding affinity (Xu et al, 2010; Balog et al,
2006). Our results for CaM-RyR2 binding affinity, from 3 independent methods,
matched each other quite well, and fit with CaM’s physiological function. So we
believe the Kd (10-20 nM) better reflects the binding affinity for CaM-RyR2 in the
native cardiac myocyte environment.
According to our data, CaM-RyR2 has a relatively slow off rate (koff = ~ 0.2
min-1), meaning the average dwell time for CaM on RyR2 is ~5 min in resting
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condition. In addition, high [Ca2+]i (500 nM) favors CaM binding to Z-line and
greatly prolongs CaM dissociation time and increases the affinity (Guo et al,
2011; Wu et al, 2007). So the increased CaM-RyR2 affinity during the Ca2+
transient (< 1 second) during which intracellular [Ca2+] could be as high as
handreds micromolar; this would further enhance CaM saturation at all RyR2
monomers in the physiological beat-to-beat situation. Furthermore, it was
proposed that CaM can switch between two binding sites with 33Å distance on
RyR during each cycle of contraction (Tripathy et al, 1995; Samso and
Wagenknecht 2002). The two-site switch involves two sets of association and
dissociation process, which might be unlikely to occur within the very short
systolic Ca2+ time according to our measured kinetics. Taken together, we think
that CaM is a residently associated protein to RyR2 and is anchored to at least
residues 3583-3603. But we can not exclude the possibility of beat-to-beat RyR2
regulation by CaM, because in RyR2ADA/ADA mutant sustained peak time for Ca2+
transient were observed, indicating the possible importance of resident CaM for
RyR2 shut-off (Yamaguchi et al, 2007). It is possible that, during Ca2+ transient,
RyR opening and conformation change could alter anchored CaM function,
where binding of Ca2+ to CaM would facilitate the termination of Ca2+ release.
Nearly all Z-line bound CaM is on RyR2
One of the important aspects in this study is that, through knock-in mice
(RyR2ADA/+) we estimate that > 90% of total Z-line associated CaM is on RyR2,
meaning ~1.1 μM CaM is associated with RyR2. This result is consistent with
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FKBP12.6 Bmax measurements (Guo et al, 2010) and the estimated concentration
of RyR2 monomers in rat ventricular myocytes (Bers and Stiffel, 1993), revealing
that other CaM binding sites at the Z-line are ~0.07μM. Since LTCC is also
known to bind CaM and at the same location as RyR2, and there are ~32 RyR2
monomers per LTCC in rat myocytes (Bers and Stiffel, 1993), the calculated
LTCC-bound CaM could be ~0.04 uM consistent with our result. We can see that
RyR2 is the quantitatively dominant CaM binding site at the Z-line. The total
cellular CaM concentration in cardiac myocytes is about 2-5 μM in different
species (Maier et al, 2006). From this we can see that RyR2 is also an overall
major binding site for CaM, and that any binding affinity variation in RyR2, like in
HF, could cause changes in cellular free [CaM] and consequent distribution.
Defective RyR2-CaM interaction and SR Ca2+ release
Yamaguchi (2007) explained the important link between CaM-RyR2
interaction and abnormal SR Ca2+ leak, and cardiac hypertrophy in RyR2ADA
homozygous mice. But, due to the early death of RyR2ADA homozygous mice
(Yamaguchi et al, 2007), the relation between defective CaM-RyR2 interaction
and arrythmogenesis is not clear. However, RyR2ADA heterozygous mice can
survive to provide us an excellent model for our study. We notice a similarity
between RyR2ADA KI mice and CPVT1 mutation KI mice (RyR2-R2474S)
(Stephan et al, 2008), that is both homozygous KI mice do not survive but
heterozygous can survive similar to WT. Furthermore, decreased CaM-RyR2
binding affinity has been reported in CPVT1 KI mice (Xu et al, 2010). So for
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functional tests, we focused on the SR Ca2+ release under stress conditions in
RyR2ADA heterozygous mice. In permeabilized cells, when [Ca2+]i is tightly
controlled at 50 nM, we only observed a moderate Ca2+ spark frequency increase
for RyR2ADA/+ mice. This moderate Ca2+ leakiness explains why the heterozygous
mice could survive as long as WT, unlike homozygous RyR2ADA mice which
developed severe cardiac hypertrophy and early death. For the CPVT1 mutant,
spontaneous Ca2+ releases (Ca2+ waves) which can trigger DADs, are a typical
phenomena. In our case the diastolic Ca2+ leak at resting condition in RyR2ADA/+
is insufficient to produce Ca2+ waves and triggered arrhythmias unless SR Ca2+
load is driven up by external stimulus (i.e., stress or exercise). Then we
increased intracellular [Ca2+] to 100 nM to load the SR and this produced Ca2+
waves significantly in RyR2ADA/+ mice, which indicates the hypersensitized RyR2.
There are two reasons which could be behind this phenomenon. 1), the
increased SR Ca2+ content over the threshold releases more Ca2+ than in resting
condition during the SR Ca2+ leak; 2), possible endogenous CaMKII activation,
due to increased free [CaM] (released by 50% defective CaM-RyR2 interaction)
and high Ca2+, which could activate endogenous CaMKII then further
phosphorylate and sensitize RyR2 to amplify the leakiness.
For the Ca2+ transient measurements in intact cells, ISO makes a big
difference in RyR2ADA/+ mice. We observe a prolonged Ca2+ transient decline time
constant. Since Yamaguchi (2007) reported that there is no change for Ca2+
uptake by the SR CaATPase for RyR2ADA/+ mice (Yamaguchi et al, 2007), we
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think that the prolonged Ca2+ decline might be due to delayed RyR2 closure,
which is consistent with single channel recording where CaM-RyR2 interaction
facilitates termination of Ca2+ release (Xu et al, 2004). Under ISO stimulation,
there is a decreased SR Ca2+ content and an increased fractional SR Ca2+
release for RyR2ADA/+ mice, indicating the sensitized RyR2 by CaM dissociation
could increase systolic SR Ca2+ release. Additionally, with the presence of ISO,
there is an increase of the propensity for Ca2+ waves and triggered activity (Fig
18).

This phenomenon is very similar to the situation in CPVT1 KI mice

(Uchinoumi H, et al, 2010). In resting condition, there is a mild diastolic Ca2+ leak
(Fig 17B) with unchanged Ca2+ transients and fractional release. But under ISO
stimulation, we see a dramatically increased propensity for Ca2+ wave and trigger
activity. The ADA mutation on RyR2 is not a known human disease linked
mutation, but it causes very similar phenotype as CPVT mutations. These results
imply

a

strong

link

between

defective

RyR2-CaM

interaction

and

arrhythmogenesis, and the potential mechanism underlying arrhythmia.
CaM-RyR2 binding affinity in HF myocytes
One of the most important aims for this study is to define the in situ
binding affinity for RyR2-CaM in HF myocytes and access potential pathological
impact of that. Our result indicates a 3-fold decreased binding affinity for RyR2CaM interaction in failing heart induced by MI. HF causes a reduced RyR2-CaM
association, from 70-90% to 50-70%, assuming unchanged free myocyte [CaM].
Using IP other studies have also reported less CaM bound to RyR2 in HF in
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rabbits (Ai et al, 2005) and dogs (Ono M, et al, 2010), so this seems like a
general finding in HF. Less CaM association can decrease RyR2 gating
threshold, causing abnormal Ca2+ release and triggered activation. In RyRADA/+
mice, we revealed that 50% reduction of RyR2 association leads to dramatically
increased propensity for Ca2+ wave and trigger activity in the presence

of

isoproterenol. In our HF model, the RyR2-CaM association rate is close to 50%
level,

revealing

a

strong

link

between

CaM-RyR2

disassociation

to

arrhythmogenesis in HF. Furthermore, the attenuated RyR2-CaM association in
HF could increase intracellular free [CaM], since RyR2 is a major cellular binding
site for CaM. This could change CaM cellular distribution extensively; the CaM
lost by RyR2 could be driven to the binding targets with a lower affinity than
RyR2, such as: CaMKII and adenylyl cyclase (Maier and Bers, 2002). Further
study is needed to assess such CaM redistribution and its effect in HF.
Overall we think that HF associated SR Ca2+ leak is a complicated process
in which many factors may be involved (e.g. CaM, CaMKII, FKBP12.6, redox
modification etc). Even though in normal myocytes saturating RyR2 with
FKBP12.6 only slightly reduces Ca2+ sparks (Guo et al, 2010), we could not
exclude the possibility that FKBP12.6 might inhibit pathological leaky RyRs.
Here, we for the first time have directly measured the in situ binding affinity of
RyR2-FKBP12.6 in failing heart myocytes, which revealed unchanged binding
affinity. We conclude that CaM binding to RyR2 is an important physiological
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regulator of RyR2 gating in cardiac myocytes, and that defects in this binding in
HF or CPVT may be an important molecular mechanism of triggered arrhythmias.

CHAPTER VI
Define CaM as a critical stabilizer through RyR2 unzipping
peptide (DPc10)
INTRODUCTION
A leading hypothesis explains the RyR2 dysfunction in HF and lethal arrhythmias,
such as catecholaminergic polymorphic ventricular tachycardia (CPVT), by RyR2
mutations that result in defective interaction between the N-terminal (N: 0-600)
and the central (C: 2000-2500) domains (Yamamoto T & Ikemoto 2002).
According to this concept, in the resting state, the N-terminal and central
domains interact with each other to act as a regulatory switch for channel gating
activity. This tight interdomain interaction, termed “domain zipping” serves to
stabilize the closed channel. Weakening of these interdomain interactions may
be caused by mutations in either the N-terminal or central regions of RyR2
(Uchinoumi et al, 2010) or via synthetic competition by cardiac domain peptides
(Ikemoto & Yamamoto 2002; Ikemoto 2004; Yamamoto et al, 2000) (domain
unzipping), resulting in an increased opening probability of the RyR2 and
leakiness of Ca2+. DPc10 is a synthetic peptide corresponding to 36-residue
stretch of the central domain (Gly2460-Pro2495) of RyR2 (Yamamoto & Ikemoto
2002). It has been proposed that DPc10 can specifically associate with the Nterminal domain, and thus compete with its zipping to the central domain, and
108
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that the N-domain/DPc10 association can destabilize RyR2 (via domain
unzipping), to increase Ca2+ leakiness (Oda et al, 2005). A single R2474S point
mutation in DPc10 (DPc10-mut) inhibits all of the effects that would have been
produced by DPc10. Liu et al (2005), through GFP insertion and mapping,
showed a physical proximity between N- and central domains in the 3D structure
of RyR2. They also find FRET interaction between these two regulatory domains
for CFP/YFP insertion in HEK cell, but the zipping pair (N- and central domains)
is not from the same RyR2 monomer, but from two different neighbor subunits in
one RyR2, indicating the interaction of neighboring subunits plays important role
to stabilize RyR2 (Liu et al, 2010). Taken together, these data suggest that
synthetic domain peptides bind to key subdomains of RyR2 and are capable of
mimicking disease conditions of the RyR2 channel by interfering with interdomain
interactions. The interaction between neighbor subunits is important for the RyR2
stabilization.
FKBP12 and FKBP12.6 are expressed in cardiac myocytes and can form
tight complexes with RyR2, at a stoichiometry of four FKBPs per tetrameric RyR2
channel (Bers, 2004). As such, these FKBP isoforms are considered important
RyR2 subunits, and have been reported to promote the closed channel state, but
this role is controversial in the heart. In myocytes from normal rat hearts, we
found that FKBP12 does not significantly alter Ca2+ sparks, whereas FKBP12.6 is
slightly inhibitory, and PKA-dependent RyR2 phosphorylation does not alter
FKBP12.6 binding affinity (Guo et al, 2010). Furthermore, a small fraction of
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RyR2 in native myocytes has FKBP12.6 bound (Guo et al, 2010). Two previous
studies, in which RyR2 was treated with domain peptides to mimic pathologic
Ca2+ leakage, found no direct effect of DPc10 on FKBP12.6 co-immunoprecipitation with RyR2 (Oda et al, 2005; Tateishi et al, 2009). But it is
unknown whether FKBP12.6 influences binding of DPc10 to RyR2 or the ensuing
increased Ca2+ leakage.
CaM is a ubiquitous Ca2+ binding protein that binds to the RyR2 and
modulates its channel function (Yamaguchi et al, 2003). Binding of CaM within
the cytosolic domain of RyR2 (at a site partly formed by residues 3583-3603)
inhibits channel activity both at physiological and pathophysiological cellular
[Ca2+] (Fruen et al, 2000; Balshaw et al, 2002). This implies that CaM stabilizes
the closed state of RyR2 in the resting state (Guo et al, 2006). In the 3D RyR2
structure, the CaM binding site is very close to the boundary between adjacent
subunits (Hamilton & Serysheva II, 2009). There is the suggestion that CaM
binds to two adjacent subunits of RyR (Zhang et al, 2002), and contributes to
stabilization. Interestingly, concurrent-addition of a high concentration of CaM
with DPc10 in WT cardiomyocytes reduced the Ca spark frequency compared to
addition of DPc10 alone (Ono et al, 2010). Furthermore, in the CPVT mutant
myocytes where beta-adrenergic stimulation leads to defective interdomain
interaction, the affinity of CaM binding to the RyR2 is lower than that of WT
myocytes (Xu et al, 2010). In addition, Ono et al (2010) also reported that the
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CaM binding affinity to RyR2 in the failing heart is significantly reduced compared
to that of normal RyR2.
DPc10 and related RyR2 peptides may, therefore, serve as useful
molecular probes to study the channel’s function-structure relationship. However,
the details of DPc10 binding to RyR2, including affinity and kinetics, are still
unknown. In this study, our goal was to characterize the binding of DPc10 to the
RyR2 in the relatively intact environment of saponin-permeabilized rat ventricular
myocytes. We used fluorescent DPc10 to measure the affinity and kinetics of
DPc10 binding to RyR2, and its influence on CaM and FKBP12.6 binding and
function, and how DPc10 alters CaM and FKBP12.6 binding.
MATERIALS AND METHODS
Domain peptide
DPc10 peptides unlabeled and labeled with 5-carboxyfluorescein or HiLyte
FluorTM 647 at N-terminal were synthesized at AnaSpec (Fremont, CA). The
DPc10 sequence is:
2460-GFCPDHKAAMVLFLDRVYGIEVQDFLLHLLEVGFLP-2495.
Laser scanning confocal microscopy
Confocal images were measured using a Biorad Radiance 2100 laser
scanning confocal microscope equipped with an Argon ion laser, Green HeNe
laser and a Nikon Fluo 40 x oil objective lens. FRET between CaM and DPc10
were performed on Olympus FV1000 confocal microscope. All experiments were
done at room temperature
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F-DPc 10 washin/off in permeabilized myocytes
See details in chapter IV
Ca2+ sparks in permeabilized cells using confocal microscopy
See details in chapter IV

FRET measurements
For the FRET between CaM and DPc10, we used Alexa Fluor 568
attached at the C-lobe of CaM (AF568-110-CaM) or Alexa Fluor 488 at N-lobe
(AF488-34-CaM) as the donor, and HiLyte FluorTM647-DPc10 (HF647-DPc10) as
the acceptor. AF488, AF568- and HF647- were excited with separate lasers of
488 nm, 543 nm and 635 nm, respectively. Emission fluorescence intensity data
were obtained at 500-530 nm for AF488-34-CaM, 560-620 nm for AF568-110CaM and 655-755 nm for HF647-DPc10. Fig 20 shows the spectrum of FRET
probes.
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RESULTS
Binding kinetics of F-DPc10 in permeabilized cardiac myocytes
To characterize DPc10 binding kinetics at the Z-lines, we performed FDPc10 wash-in (500 nmol/L), wash-off experiments in permeabilized myocytes
(Fig 21A). We observed very slow association (Wwash-in = 79.0 ± 3.2 min) and
dissociation processes (Wwash-out = 149.8 ± 4.4 min), compared to FKBP12.6
measurements (Guo T, et al, 2010). From the wash-in/wash-off measurements,
we calculated the association and dissociation rates constants, kon and koff,
according to:
kwash-in = [F-DPc10]kon + koff

Eq 1

where kwash-out § koff and k = 1/W (s). Accordingly, kon = 188 ± 37 (s-1 M-1),
and koff = 0.12 ± 0.01 (10-3 s-1). Based on these values and Kd = koff/kon, F-DPc10
binds at the Z-line with Kd = 644 ± 149 nmol/L.
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Fig 21: F-DPc10 binding at the myocyte Z-line (collaboration with
Oda Tetsuro). A, striation pattern of saponin-permeabilized myocytes
incubated in 5 μmol/L F-DPc10 for 3 hours, and illustration of DPc10
binding pocket between N-(blue) and central (red) domains in RyR2. B,
Time course of F-DPc10 (0.5 μmol/L) wash-in and wash-out.
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We were intrigued by the slow kin, and conducted measurements to further
understand the structural basis of this slow association. Thus, we tested the
hypothesis that, at resting [Ca2+]i, normally RyR2 is in closed situation, where Nand central domains are in the tightly zipped condition, which sterically hindered
DPc10 access to its RyR2 binding site. If the N-terminal and central domains are
tightly “zipped” to each other, this interaction may occlude the DPc10 binding site
on the RyR2, thus limiting the DPc10 kon. Alternatively, a limiting factor may be
the rate at which DPc10 adopts a conformation that is competent to bind to
RyR2. To discern between these mechanisms, we determined the effect of [FDPc10] on kin which should increase linearly with [F-DPc10], according to Eq 1.
This is not what was observed, however.

Instead, a 10-fold increase in [F-

DPc10] (from 0.5 to 5μmol/L) had no significant effect on the Wwash-in of F-DPc10
but significantly increased Bmax (Fig 21A, B). This result suggests that F-DPc10
association at its RyR2 binding site is restricted by a factor residing on RyR2,
which is probably the binding pocket opening rate.

117

B

15

60

10
5
0

0

50

100

150

200

0.5 P M

80

5 PM

0

20

0.5 P M

0.5 P M
10

100
NS

(5)

(5)

(5) (5)

Bmax

Wwashin

40
20
0

of F-DPc10 (min)

20

F-DPc10 Bmax (a.u.)

5 PM

*

w ashin

25

5 PM

30

W

F-DPc10 Binding (a.u.)

A

Time (min)

Fig 22: Wash-in time course for different [F-DPc10] (collaboration
with Oda Tetsuro). A, Time course wash-in curve for different [F-DPc10]
(0.5 and 5μmol/L). B Wwash-in and Bmax for different [F-DPc10]. Data are
reported as mean ± SE.
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In our working model, under resting conditions, the RyR closed state is
stabilized by the interaction between the N-terminal and central domain in the
"zipped" state. We hypothesized that conditions that promote RyR opening will
result in a higher rate of unzipping, and a faster F-DPc10 wash-in rate. To test
this, we first monitored F-DPc10 wash-in at elevated Ca2+ (500 nmol/L) and
found slightly faster association vs. 50nmol/L [Ca2+]i (Fig 23A). Next, we preincubated the myocytes with ryanodine (100 μmol/L) plus caffeine (5 mmol/L),
which has been reported to cause RyR2 domain unzipping in HEK293 cells (Liu
Z, et al, 2010), and found a significantly faster F-DPc10 association (Fig 23B).
However, the most significant effect was seen after pre-incubating myocytes with
a saturating concentration of non-fluorescent DPc10 (NF-DPc10). This treatment
significantly accelerated F-DPc10 association by a factor of ~2 (Fig 23A). Neither
treatment significantly altered Bmax (Fig 23A & B). Assuming that koff of NFDPc10 is the same as for F-DPc10 and using Eq 1, the kon is increased by 3.2fold by unzipping by prebinding NF-DPc10 to the RyR2. These results are
consistent with a small fraction of channels being in the unzipped state even at
500 nmol/L Ca2+ or wih caffeine +ryanodine. Moreover, it would seem that the
RyR2 open state (favored by caffeine-ryanodine) differs from the unzipped state
(with DPc10 bound).
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Fig 23: Effect of RyR2 channel modulators on the kinetics of FDPc10 Z-line association (collaboration with Oda Tetsuro). A, Time
course of F-DPc10 (0.5 μmol/L) Z-line binding in low [Ca2+]i, high [Ca2+]i, or
after a 3 hr pre-equilibration with saturating [NF-DPc10] (2 μmol/L) in low
[Ca2+]i . B, Time course of F-DPc10 (5 μmol/L) Z-line binding after a 3 hr
pre-equilibration in internal solution containing ryanodine (100 μmol/L) and
caffeine (5 mmol/L). Data are reported as mean ± SE.
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Effect of DPc10 on CaM and FKBP12.6 binding at the myocyte Z-line
Both FKBP12.6 and CaM bind to the RyR2 and can reduce channel
opening, which might inhibit DPc10 binding.

Fig 24A shows representative

confocal images of FKBP12.6 (100 nmol/L) and CaM (1 μmol/L) effects on FDPc10 binding, as detected after a 200 min incubation with F-DPc10. While preequilibration with CaM (1 μmol/L) greatly reduced F-DPc10 binding, pretreatment with FKBP12.6 (100 nmol/L) did not alter F-DPc10 binding in
permeabilized myocytes. Fig 24B shows the time course of F-DPc10 wash-in
with or without pretreatment of 100 nmol/L FKBP12.6 or 1 μmol/L CaM.
Saturation of RyR2 with FKBP12.6 (100 nmol/L) did not alter either F-DPc10
maximal binding (Bmax) or Wwash-in. In contrast, saturation of RyR2 with CaM
dramatically reduced F-DPc10 Bmax and dramatically slowed DPc10 access to its
binding site, as indicated by the increase in Wwash-in (Fig 24C). We infer that CaM
stabilizes the domain interaction between N-terminal and central domains in the
"zipped" state, and may thereby reduce DPc10 access to its binding site.
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Fig 24: Effects of FKBP12.6 and CaM on F-DPc10 binding at Zline. A, Representative confocal images illustrating the effect of FKBP12.6
(100 nmol/L), and CaM (1 μmol/L) on the F-DPc10 (5 μmol/L) binding at
the Z-lines. B, Time course of F-DPc10 (5 μmol/L) wash-in (circles), and in
the presence of FKBP12.6 (100 nmol/L, diamonds) or CaM (1 μmol/L,
triangles). C, Summary of fitting parameters (Bmax and Wwash-in).
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Next, we asked whether RyR channel activation by DPc10 is inhibited by
FKBP12.6 or CaM. We assessed Ca2+ sparks in permeabilized myocytes
perfused with internal solution containing 50 nmol/L free Ca2+ plus 1 μmol/L AIP
(to inhibit CaMKII activity). Line-scan images were recorded after 3 hr
incubations under control conditions, and in the presence of 5 μmol/L DPc10,
with or without 1 μmol/L CaM or 100 nmol/L FKBP12.6 (Fig 25A). DPc10 robustly
increased Ca2+ spark frequency (CaSpF) vs. control, an effect almost completely
blocked by CaM (Figure 25B). However, CaSpF activation by DPc10 is only
slightly decreased by FKBP12.6 (Fig 25B). In DPc10-treated permeabilized
myocytes, Ca2+ spark full width at half maximum (FWHM) and full duration at half
maximum (FDHM) is significantly increased compared to control, and decreased
when pre-treated with CaM ( Table 2).
Since Ca2+ spark frequency strongly depends on the SR Ca2+ content, we
also assessed SR Ca2+ content as the amplitude of caffeine-induced Ca2+
transient (Fig 25B, right). With DPc10 alone or with FKBP12.6, SR Ca2+ load was
significantly lower than under control conditions. In contrast, treatment with CaM
plus DPc10 resulted in no significant decrease in SR Ca2+ content vs control.
Thus, the increased CaSpF in the presence of FKBP12.6 plus DPc10 cannot be
secondary to increased SR Ca2+ content, which actually decreased. These
results are consistent with a DPc10-induced increase in RyR2 channel activity
resulting from defective interaction between N-terminal and central domains. This
also agrees with the lack of FKBP12.6 effect on F-DPc10 binding kinetics (Fig
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25B) and the potent inhibition of DPc10 binding by CaM, which may promote the
“zipped” state and inhibit DPc10 access.
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Fig 25: Effects of FKBP12.6 and CaM on DPc10 binding and Ca2+
sparks in permeabilized cardiomyocytes (collaboration with Oda
Tetsuro). A, Ca sparks measured using Fluo-4 as Ca2+ indicator.
Representative line-scan images acquired after addition of DPc10 (5
μmol/L), DPc10 (5 μmol/L) plus FKBP12.6 (100 nmol/L), and DPc10 (5
μmol/L) plus CaM (1 μmol/L). [Ca2+]i = 50 nmol/L. B, Summary of Ca2+
spark frequency and SR Ca2+ content. Data are reported as mean ± SE.
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Table 2. Ca2+ spark characteristics in saponin-permeabilized
cardiomyocytes

No. of
Sparks

Peak
(F/F0)

FWHM
(µm)

FDHM
(ms)

Control

1761

0.499 ± 0.004

1.28 ± 0.01

55.7 ± 0.67

+DPc10

1467

0.475 ± 0.004*

1.34 ± 0.01*

58.5 ± 1.00*

+FKBP12.6/DPc10

1921

0.439 ± 0.002*

1.21 ± 0.01*

60.5 ± 0.73*

+CaM/DPc10

2195

0.467 ± 0.003*

1.23 ± 0.01*

56.9 ± 0.74
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Effect of DPc10 on FKBP12.6 and CaM binding in permeabilized myocytes
To examine the converse influence that DPc10 may have on FKBP12.6
and CaM binding to RyR2 in situ, we used fluorescent FKBP12.6 and CaM
variants labeled with Alexa Fluor 488 or 568 (AF488 and AF568, respectively).
These fluorescent proteins were added to saponin permeabilized myocytes with
or without pre-equilibration with saturating DPc10 concentration. First, we found
that AF488-FKBP12.6 at a 1 nmol/L (near its Kd) (Guo T, et al, 2010), forms a
striated pattern that is not affected by pre-incubation of 5 μmol/L DPc10. (Fig 26A
& B). Thus, DPc10 does not influence FKBP12.6 binding to RyR2. Next, we
measured FRET between AF488-FKBP12.6 (donor) and AF568-34-CaM
(acceptor in the N-domain) at a [CaM] near the Kd (20 nmol/L), in order to only
detect CaM that is specifically bound to the RyR2 (Fig 27A).

Using direct

excitation at 543 nm (emission at >600 nm) we detected total CaM at the Z-lines
(Fig 27A). We also did this with high [CaM] (500 nmol/L) which saturates RyR2
with CaM under control conditions. Fig 27B shows that pre-treatment with DPc10
significantly reduced CaM binding (at 20 nmol/L CaM) both at the RyR2 and
overall at the Z-lines, and by similar proportions. Even at high AF568-34-CaM
levels (500 nmol/L) DPc10-treated myocytes exhibited reduced CaM binding at
the RyR2 (FRET) and at the Z-lines (Total) vs. control (Fig 27B). Thus, once FDPc10 binds to the RyR2 and decreases N-terminal-central domain interactions,
it reduces the CaM affinity for RyR2. Taken together, these results show that
DPc10 and CaM binding to RyR2 are mutually inhibitory. To test whether DPc10

127
and CaM bind at the same or nearby RyR2 sites we measured FRET between
CaM and DPc10.
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Fig 26: The effect of DPc10 on FKBP12.6 binding to RyR2 in
cardiac myocytes (collaboration with Oda Tetsuro). A. Representative
image for FKBP12.6 binding (100nM) with or without DPc10 (5μM)
pretreatment. B. Average fluorescence for FKBP12.6 binding with/without
DPc 10.
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Fig 27: The effect of DPc10 on CaM binding to RyR2 in cardiac
myocytes (collaboration with Oda Tetsuro). A. Representative confocal
image of the effect of DPc10 on AF568-CaM binding at the Z-lines (total
CaM, Ex =543 nm) and at the RyR2 detected by FRET between AF488FKBP12.6 (donor) and AF568-CaM (acceptor) (Ex =488 nm). Myocytes were
incubated with 5 μmol/L DPc10 (3 hrs) before adding CaM. B. Summary of
RyR2-bound CaM and Z-line total CaM binding of DPc10 pretreatment.
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FRET between CaM and DPc10
We used FRET to assess the distance between a fluorescence donor
probe (AF568) at the C-lobe of CaM (AF568-110-CaM) and HiLyte Fluor 647
(HF647) as acceptor probe on the N-terminus of DPc10 (HF647-DPc10). We
utilized the acceptor photobleaching approach with measurement of the resultant
increase in donor (AF568-110-CaM) fluorescence in saponin permeabilized
myocytes. To use this approach quantitatively, all acceptor sites must be loaded,
so that all donors can participate in FRET.
Our results show that it is impractical to saturate RyR2 with both CaM and
DPc10 (Fig 24B and 27B). To overcome this challenge, we pre-equilibrated the
myocytes with saturating HF647-DPc10, thus loading all DPc10 binding sites on
RyR2. Then when we add AF568-110-CaM (500 nmol/L) ~50% of RyR2s have
donor, but all have acceptor, allowing quantitative analysis of enhanced donor
fluorescence upon acceptor photobleach. Fig 28A shows selective photobleach
of HF647-DPc10 (at 635 nm) in only the central region of the myocyte, and donor
fluorescence was enhanced only in that region, indicating that donors and
acceptors are within FRET range.
To rule out the possibility that there is energy transfer between a donor
and multiple acceptors, we measured the relationship between donor
fluorescence enhancement and acceptor photobleach, and found a linear
relationship (Fig 28B), which indicates that there is a 1:1 stoichiometry for the
CaM-DPc10 FRET. We interpret this result as clear evidence that the FRET
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efficiency (E) between AF568-110-CaM and HF647-DPc10 reflects the proximity
of one CaM to one DPc10. E and donor-acceptor distance calculations are
described in the methods section (chapter IV).
The FRET efficiency between AF568-110-CaM and HF647-DPc10 upon
98.2 ± 0.2 % acceptor photobleach was E= 0.89 ± 0.01 (n=8). This corresponds
to a distance of 53 ± 1 Å (Fig 28C), based on R0 = 75 Å for the AF568-HF647
donor-acceptor pair. With an alternative donor probe (AF488), this time attached
at the N-lobe of CaM, and the same acceptor (HF647) on DPc10, we measured
E= 0.27 ± 0.02 which corresponds to an interprobe distance of 63 ± 1 Å (Fig
28C). Thus, this result shows that the donor probes on CaM are 53-63 Å from the
acceptor on DPc10, suggesting that CaM and DPc10 can simultaneously bind at
distinct, yet nearby sites within the RyR2 structure. This again favors an allosteric
rather than competitive basis for the mutual inhibition seen between CaM and
DPc10 binding to the RyR2.
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Fig 28: FRET between F-CaM and F-DPc10. A, Confocal images
show FRET between AF568-110-CaM (donor) and HF647-DPc10
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DISCUSSION
We used fluorescent DPc10, FKBP12.6, CaM and confocal microscopy of
permeabilized cardiomyocytes and found that (1) DPc10 access to its binding
site is sterically hindered in resting (zipped) RyR2, (2) F-DPc10 wash-in kinetics
provide a sensitive measure of the RyR2 unzipped state in permeabilized
myocytes, (3) DPc10 and CaM binding to RyR2 are mutually inhibitory (via
allosteric rather than competitive interaction), and (4) DPc10 and CaM are
physically 50-60 Å from each other.

Access of DPc10 to Its RyR2 Binding Site Is Restricted
We found that both the wash-in and wash-off kinetics of F-DPc10 binding
(kwash-in and kwash-off) are extremely slow (Fig 21B). The calculated kon for F-DPc10
is about 1800-fold slower than that we measured for FKBP12.6 under similar
conditions (Guo T, et al, 2010). This suggests either that DPc10 very slowly
adopts a conformation that can bind RyR2, or that the DPc10 binding site on
RyR2 becomes available only very slowly. The insensitivity of kwash-in to higher FDPc10 concentration (Fig 22A), is most consistent with the latter interpretation,
indicating that kon is limited by RyR2 properties that restrict the access of DPc10
to its binding site. Further supporting this hypothesis, pretreatment with NFDPc10 (Fig 23A) robustly increased kon (~320%). We infer that the bound NFDPc10 shifted RyR2 to the unzipped state allowing better access and exchange
with F-DPc10. We also found that enhancing RyR2 open state (by elevated
[Ca2+] or caffeine+ryanodine) hastened the F-DPc10 association (Fig 23A, B).
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However, these effects on kwash-in were small compared to that of pre-binding NFDPc10 (~15%), despite the very strong channel activation expected. From this
and other work (Liu et al, 2010), we suggest that the unzipped and open states
differ, although unzipping may enhance opening and opening may enhance the
unzipping transition (and DPc10 access).

Relationship between FKBP12.6 and DPc10 binding to RyR2
FKBP12.6 has been found to quiet RyR2 channel opening (Prestle et al.
2001; Xin et al. 2002; George et al. 2003; Yano et al. 2003), but this is an
intensely controversial issue (Timerman et al. 1996; Barg et al. 1997; Xiao et al.
2007; Jones et al. 2008; Bers 2012) and FKBP12.6 may only inhibit
pathologically leaky RyRs (Yano M, et al, 2000). Since more than 80% of the
RyRs in cardiomyocytes have no natively-bound FKBP12.6 (Guo T, et al, 2010),
adding saturating concentrations of exogenous FKBP12.6 ought to decrease
Ca2+ leak caused by DPc10-induced unzipping. Here, we found that FKBP12.6
has no effect on either DPc10 binding (Bmax or Wwash-in) or vice-versa (Fig 24B and
Fig 26) and does not quiet the activating effect of DPc10 on the CaSpF (Fig
25B). That is similar to our previous myocyte studies, where FKBP12.6 had very
minor effects on Ca2+ sparks (Guo et al, 2010). Taken together, these results
suggest that DPc10 and FKBP12.6 modulate RyR2 function through independent
mechanisms.

Relationship between CaM and DPc10 Binding to RyR2
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In myocytes containing a CPVT-linked RyR2 mutation E-adrenergic
stimulation decreases CaM binding at the Z-lines, and this effect is mimicked in
healthy myocytes by treatment with DPc10 (Ono et al, 2010). Here, we used
methods designed to monitor CaM and DPc10 binding specifically at RyR2,
aiming to understand the structural basis of the inhibition of CaM-RyR binding by
DPc10. One important finding in the present study is that saturating CaM binding
at the RyR2 dramatically reduced F-DPc10 binding and Ca2+ spark activation (Fig
24 & 25), presumably by stabilizing the zipped RyR2 state.
Our novel FRET-based method allows direct assessment of CaM-RyR
binding in the native cardiac myocyte environment (using FKBP12.6-CaM FRET)
(Guo et al, 2011). Using this method, we found that unzipping the RyR by
treatment with saturating [DPc10], reciprocally inhibits CaM binding to RyR2 (Fig
26B, right panel). There are two possible explanations for this reciprocal binding
inhibition: (1) DPc10 and CaM compete to bind at overlapping sites (orthosteric
mechanism) or (2) the DPc10 and CaM binding sites are separate but coupled in
a mutually inhibitory interaction (allosteric mechanism).
To discern between these possibilities we assessed if CaM and DPc10
can coexist on RyR2. In Fig 27A, we show strong FRET between donor-labeled
CaM and acceptor-labeled DPc10 at the Z-lines, indicating that CaM and DPc10
binding sites in neighboring regions are simultaneously occupied. This
conclusion is further supported by FRET measurements using two different
donor-acceptor pairs and two different labeling sites on CaM, which indicate
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distances of 63 ± 1 and 53 ± 1 Å between DPc10 and the N- and C-lobes of
CaM, respectively (Fig 28C). Taken together, these results strongly support the
conclusion that DPc10 and CaM bind at separate sites on RyR2, and they
interact through an allosteric mutually inhibitory mechanism.
Our working hypothesis (Fig 29) is as follows. The resting zipped RyR2
does not readily allow DPc10 access to its site (i) and CaM binding at a different
site may stabilize this zipped state (iii). We suppose the RyR2 can transition
spontaneously between this zipped and the unzipped state (i-ii) but that the low
probability at rest cause the slow, but eventual access of DPc10 to its site. This
transition may be favored by channel opening (Ca2+, caffeine, ryanodine) and
also in pathological conditions (e.g. HF). Once the central domain-mimicking
DPc10 gains access and binds, it stabilizes the unzipped state (ii) which
reciprocally facilitates channel opening and inhibits CaM binding (iv).
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Fig 29: Proposed model of the interaction between N-terminal
and central domains. Kinetics results (Figures 2-4) suggest that F-DPc10
access to its binding site is controlled by inter-domain interaction within
RyR2. (i) The F-DPc10 access is sterically hindered in resting normal
RyR2 (“zipped” state). (ii) Pre-treatment of RyR2 with physiological,
pharmacological, or disease-mimetic agents that promote unzipping
increase the F-DPc10 association rate. (iii) CaM inhibits the F-DPc10
binding to RyR2. (iv) DPc10 binding to RyR2 inhibits CaM binding to RyR2.

CHAPTER VII
SUMMARY
The aim of my dissertation is to understand the regulation of RyR2. The
whole dissertation is composed of two parts. The first part focused on RyR2-CaM
interaction. The second focused on synthetic RyR2 domain peptide (DPc10),
which worked as a powerful molecular tool for RyR2 functional and structural
studies.
CaM has been long identified as an important cardiac RyR regulator.
Broad studies suggest CaM is a critical RyR2 stabilizer (Xu L, et al, 2004, Guo T,
et al, 2006) and CaM-RyR2 interaction is a critical molecular substrate for
arrhythmias and HF pathogenesis (Yamaguchi N, et al, 2007; Ai X, et al, 2005;
Ono M, et al, 2010; Xu X, et al, 2010), but the in situ binding properties for CaMRyR2 are still unknown. Here we, Using FRET detection and permeabilized
myocytes, identified RyR2-bound CaM from other potential targets and revealed
that CaM binds to RyR2 with high affinity (Kd =10-20 nM) in myocytes. Therefore
physiologically CaM is bound to > 70% of RyR2 monomers and inhibits SR Ca2+
release. Using RyR2ADA/+ knock-in mice in which half of the RyR2-CaM binding
is suppressed, we estimated that >90% of Z-line CaM is RyR2-bound and identify
RyR2 as one of main CaM cellular binding sites. In consistence with binding
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properties studies, functional tests indicated a higher propensity for Ca2+ waves
in RyR2ADA/+ mice upon ISO challenge. In a post MI rat HF model, I detected a
decrease binding affinity for CaM-RyR2 (Kd = ~51nM, ~3 fold increase) and
unchanged binding affinity for FKBP12.6-RyR2 (Kd = ~0.8nM).
The defective interaction between interdomains (the N-terminal and the
central domains) is a leading hypothesis to explain the RyR2 dysfunction in HF
and lethal arrhythmias, such as CPVT. And DPc10 can bind to RyR2 and
recapitulate this arrhythmogenic RyR2 leakiness by unzipping N- and centraldomains. In this study fluorescently-labeled DPc10, FKBP12.6, and CaM were
used to characterize the binding properties of DPc10 to RyR2 in permeabilized
rat ventricular myocytes. DPc10 access to its binding site is extremely slow in
resting RyR2, but accelerated by promoting RyR2 opening or unzipping (by
unlabeled DPc10). RyR2-bound CaM (but not FKBP12.6) drastically slowed
DPc10 binding. Conversely, DPc10 binding significantly reduced CaM (but not
FKBP12.6) binding to the RyR2. FRET measurements indicate that DPc10 and
CaM binding sites are separate.
Since CaM and FKBP12.6 are both regarded as important RyR stabilizer
and implicated broadly in HF, hypertrophy and arrhythmia genesis. And
FKBP12.6 is still a highly controversial issue in cardiology (this was reviewed in
chapter II, FK-506 Binding Protein section). Here, mainly based on the data from
our lab, I made a brief comparison between these two important RyR2
stabilizers, which suggested CaM has more prominent effect for RyR2 gating

140
than FKBP12.6 does. However, I can’t exclude the possibility that FKBP12.6
may modulate RyR2 activities in a subtle way which is undetectable by our
experiment, like non-spark Ca2+ leak by RyR2.
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Table 3. Comparison between CaM and FKBP12.6 as RyR2 stabilizer

CaM

FKBP12.6

Kd and RyR2 High affinity (Kd = 10-20nM),
monomer
intracellular [CaM] = 50-70nM
association rate (a), 70-90% RyR2 monomers
are associated with CaM.

High affinity (Kd = 1nM),
but
low
endogenous
FKBP12.6, 10-20% RyR2
monomers are associated
with FKBP12.6. (b)
ADA
Phenotype of RyR2
knock-in mice, in FKBP12.6 knock-out mice,
bioengineered
homozygous,
severe no obvious phenotype at
mice
hypertrophy and early death. resting condition. (d)
(c)
Kd
in
HF
Increased
No change
myocytes
Ca2+
spark 50-70% decrease (e)
inhibition
in
myocytes
in
staturated
condition
Association can
Yes
keep RyR2 in
zipping
condition

~20% decrease (b)

If RyR2 is in Kd (RyR2-CaM) increased
unzipping state

No change for Kd (RyR2FKBP12.6)

(a), Wu x, et al, 2006
(b), Guo T, et al, 2010
(c), Yamaguchi N, et al, 2007
(d), Wehrens X, et al, 2003
(e), Guo T, et al, 2006

No
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Future studies
For the future studies, these projects can be taken further to address the
specific reasons for pathologically decreased CaM-RyR2 affinity, like: (1)
phosphorylation by PKA or CaMKII, because the phosphorylation sites (S2808 by
PKA and S2814 by CaMKII) are close to CaM docking pocket in RyR2 3D
structure (Xing M, et al, 2007), (2) RyR2 modification by redox. For DPc10
studies, F-DPc10 wash-in kinetics can be used in the more native environment of
permeabilized cardiomyocytes to evaluate domain interaction between the Nterminal and central domains of RyR2. This could serve as a powerful and
versatile investigative tool in pre-clinical and clinical studies with respect to the
domain unzipping hypothesis. For example, the time course of F-DPc10 wash-in
can be monitored in myocytes from failing hearts in which “unzipped” state had
already taken place (Oda T, et al, 2005; Ono M, et al, 2010), or to gauge RyR2
function under pathological conditions (e.g., oxidative stress, phosphorylation
state etc) and in the evaluation (or validation) of drug candidates that act to
stabilize the RyR2 “zipped” state (Oda T, et al, 2005).
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